WO1989005859A1 - Agrobacterium mediated transformation of germinating plant seeds - Google Patents

Agrobacterium mediated transformation of germinating plant seeds Download PDF

Info

Publication number
WO1989005859A1
WO1989005859A1 PCT/US1988/004464 US8804464W WO8905859A1 WO 1989005859 A1 WO1989005859 A1 WO 1989005859A1 US 8804464 W US8804464 W US 8804464W WO 8905859 A1 WO8905859 A1 WO 8905859A1
Authority
WO
WIPO (PCT)
Prior art keywords
plant
gene
plants
agrobacterium
transfer
Prior art date
Application number
PCT/US1988/004464
Other languages
French (fr)
Inventor
Paula P. Chee
Stephen L. Goldman
Anne C. F. Graves
Jerry L. Slightom
Original Assignee
The Upjohn Company
Regents Of The University Of Toledo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Upjohn Company, Regents Of The University Of Toledo filed Critical The Upjohn Company
Priority to AT8989900780T priority Critical patent/ATE105585T1/en
Priority to DE3889546T priority patent/DE3889546T2/en
Priority to EP89900780A priority patent/EP0397687B1/en
Publication of WO1989005859A1 publication Critical patent/WO1989005859A1/en
Priority to DK126690A priority patent/DK126690A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8202Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by biological means, e.g. cell mediated or natural vector
    • C12N15/8205Agrobacterium mediated transformation
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01HNEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H1/00Processes for modifying genotypes ; Plants characterised by associated natural traits

Definitions

  • This invention relates to a process for transforming the germinating seed of a plant and the use of said process to produce transformed plants, particularly dicotyledonous plants.
  • tissue culture procedures have not been established for many crop species. In most cases, gene transfers into crop species have been limited to transformed callus, not whole crop plants. In addition, tissue culture procedures can result in rearrangement of the inserted DNA; or somatic mutations may occur and result in the loss or alteration of desirable genetic traits accumulated by the expertise of many years of plant breeding.
  • Agrobacterium-mediated gene transfers are by far the most widely used gene transfer techniques, but the use of Agrobacterium strains may be limited because they do not efficiently infect monocotyledonous cereal crop species.
  • recent reports (Hooykaas-Van Slogteren et al., 1984; Hernalsteens et al., 1984; Graves and Goldman, 1986; Grimsley et al., 1987; Schafer et al., 1987; Bytebier et al., 1987) suggest that conditions exist whereby Agrobacterium strains can bind to monocotyledonous plant cells and transfer their T-DNA regions into these cells.
  • leguminous plants The development of gene transfer techniques for leguminous plants is of commercial interest because it facilitates the development of new cultivars with improved disease resistance, tolerance to specific herbicides and increased nutritional value.
  • these dicotyledonous species are susceptible to Agrobacterium infections (Facciotti et al., 1985; Owens and Cress, 1985; Byrne et al., 1987)
  • its use for transformation is limited due to the lack of available and efficient regeneration procedures, especially for transformed tissues.
  • Extension of this technique to germinating seed of leguminous plants such as Phaseolus vulgaris., the common bean is of great importance because regeneration procedures are not available, let alone the regeneration of transformed undifferentiated tissues.
  • the process of this invention represents (1) an improvement of the Graves and Goldman (1986) technique for the transformation of the seeds of monocotyledous plants and (2) its extension to dicotyledonous plants.
  • a process for producing a transgenic plant which comprises:
  • inoculations with virulent Agrobacterium strain A208 were done at various times after initiating germination, between 6 to 96 hours. Successful transformation was scored by gall formation on the developing seedlings, the results of inoculating 50 seeds for each time interval is presented in Table I. Seeds allowed to germinate between 24 to 48 hours were found to be the most susceptible to Agrobacterium infections. Between 70% to 80% of these inoculated seeds gave rise to seedlings with galls formed either on the hypocotyl, epicotyl, cotyledonary node, or distributed throughout the base of the plant.
  • a preferred method of inoculation is with a virulent or non-virulent Agrobacterium strain containing a transferable DNA cis or trans plasmid
  • a particularly preferred manner of practicing the process on dicots involves removing one of the cotyledons prior to inoculation. This step increases access of the strain to the mesocotyl region wherein the meristematic cells are generated.
  • the method of this invention is simple, rapid, avoids the use of any tissue culture techniques, and transformed plants can be obtained directly. Also provided are:
  • Transgenic plants prepared by the process of this invention Preferred are dicotyledonous transgenic plants. Especially preferred are dicotyldonous plants of the family leguminoseae. such as phaseolus vulgaris and Glycinus max. DESCRIPTION OF THE PREFERRED EMBODIMENT
  • Germinating seeds are inoculated with either virulent or non- virulent Agrobacterium tumefacien or Agrobacterium rhizogenes strains which contain the binary plasmid pGA472 or PGA482 or their deriv atives. Both are available from Dr. G. An, Washington State University, Pullman, WA. This binary plasmid encodes a plant expressible NPT II gene within its T-DNA region and their derivatives contain genes that will convey useful traits to transformed species. Most plants resulting from seeds inoculated with virulent Agrobacterium strains, which also contained the binary plasmid, developed typical crown galls.
  • NPT II activity was found in the leaves of some inoculated whole plants, indicating that the binary T-DNA region was also transferred. Transfer of the binary T-DNA region was also accomplished by using avirulent strains of A. tumefaciens or rhizogenes. Results presented here show that 1.6% of the P . vulgaris and about 1% of the Glycine Max (soybean) plants were transformed, with transformation being determined by the presence of NPT II enzyme activity. Seeds of Phaseolus vulgaris cv.
  • Olathe or Glvcine max (cV.A0949) were surface sterilized with 15% Clorox for 10 minutes, followed by 4-5 rinses with distilled water and then placed on moistened paper towels in a temperature controlled Percival incubator at 28oC. and allowed to germinate for various times, 16 to 96 hours. Seed coats were removed and the decoated seeds were opened in halves (that is how cotyledons were removed from the main seed body). The mesocotyl region of the germinating seeds, with their plummule still attached, were infected with an overnight liquid culture of various Agrobacterium strains by using an Eppendorf pipetter fitted with a 27 1/2 gauge needle. Seeds were infected with virulent or avirulent A.
  • tumefaciens strains (A208, C58, C58z707 and A208/phas-zein) or A. rhizogenes strains [A4RS and A4RS(pR:B278b)pu3.3c-1].
  • the common A. tumefaciens and A. rhizogenes strains are available from ATCC, 12301 Parklawn Drive, Rockville, MD.
  • the disarmed A. rhizogenes strain RS(pRiB278b) has been described by Vilaine and Casse-Delbart (1987) Mol. Gen. Genet., 206,17 and is available from Dr. F.
  • NPT II enzyme activity was detected by the in situ gel assay as reported by Reiss et al. (1984). Briefly, 100 mg. of a leaf tissue was mixed with 20 ml . of extraction buffer in a 1.5 ml. Eppendorf tube. Tissue samples were macerated with a Konte pestle and centrifuged for 20 minutes at 4°C. A 35 ⁇ l aliquot of the supernatant solutions was electrophoresed on a non-denaturing 10% polyacrylamide gel. The gel was overlaid with a 1% agarose gel containing 67 mM. tris-maleate (pH 7.1), 42 mM. MgCl 2 .
  • Example 1 The purpose of these examples is to show that gene constructions exist, either constructed by us or others, which when transferred, integrated, and expressed in a plant will convey a useful trait to that plant.
  • Example 1 The purpose of these examples is to show that gene constructions exist, either constructed by us or others, which when transferred, integrated, and expressed in a plant will convey a useful trait to that plant.
  • Example 1 The purpose of these examples is to show that gene constructions exist, either constructed by us or others, which when transferred, integrated, and expressed in a plant will convey a useful trait to that plant.
  • Germinating P. vulgaris and G. max seeds were inoculated about 24 hours after germination with virulent and avirulent Agrobacterium strains which contained modified pGA482G [constructed by clearing the SalF fragment from pWP866 which contains the gene for gentamycin-(3)- N-acetyl-benferose III, and is available from W. Piepersberg, P-8080, Kunststoff, Federal Republic of Germany, into one of the SaIl sites in pGA482, based binary vector constructions pPhas-zein [which contains the corn beta-zein gene (Pedersen et al., 1987 and is available from Dr. B. Larkins, Purdue University, West Lafayette, IN) transcriptionally linked to the P.
  • modified pGA482G constructed by clearing the SalF fragment from pWP866 which contains the gene for gentamycin-(3)- N-acetyl-benferose III, and is available from W. Piepersberg, P-8080, Kunststoff, Federal Republic
  • Transfer and expression of the plant expressible NPT II gene contained within the T-DNA region of pGA482G was determined by removing two to three young leaves (usually obtained 10 inches or more above the wound site resulting from inoculating the germinating seeds), extracting the soluble proteins and testing for NPT II activity. From a total of 695 plants tested only 11 plants showed NPT II activity in these protein extracts. They are listed in Table II and the NPT II positive results are shown in Chart 2. About 1.6% of the surviving inoculated seeds show NPT II activity, suggesting that the T-DNA region of the binary plasmid pGA482G is integrated in the genome of these P. vulgaris plants.
  • microinjection and high-velocity microprojectiles can be used to transfer DNAs into the mesocotyl region and that transformed plants should result.
  • phaseolin Using the P. vulgaris seed storage protein gene, phaseolin, and its cDNA counterpart a mutant phaseolin gene lacking its five introns was constructed.
  • This mutant phaseolin gene (phas-minigene) retains it natural 5' and 3' plant-regulatory sequences and the construction of this plasmid (pPv3.3-cDNA) has been described by Chee et al. (1986) Gene 41:47 and Cramer et al. (1985) Proc. Natl. Acad. Sci. 82; 334 and is available from Agrigenetics Corp. Madison, WI.
  • Plasmid pPv3.3-cDNA was subjected to restriction enzyme digests, BamHI and HindIII and a 3.6 kb fragment was removed and cloned into BglII and HindIII sites of the binary vector pGA482 (An et al. (1985) EMBO. J. 4:277).
  • This construction places this mutant phaseolin gene within the right and left borders of the binary plasmid, now referred to as p/i3.3c-l, and along side of the plant expressible NPT II gene which is used for selection and identification of transformed plants.
  • the structure of binary plasmid pu3.3c-l is shown in Chart 1. 2.2 Use of pu3.3c-l
  • This binary plasmid has to be transferred into various Agrobacterium strains, i.e. A208, C58, C58:707, LBA4404 and A4RS, etc.
  • the method described here can be used to transfer the binary plasmid p ⁇ 3.3c-l into various plant species (e.g., common bean, soybean and other large seeded plants).
  • multiple copies of the phaseolin minigene can be placed into the binary plasmid by subcloning the NcoI to BamHI fragment (3 kb fragment) frompPv3.3-CDNA into NcoInd BamHI digested clone pPr 8.8 g (available from J.
  • the orientation of the new phaseolin insert(s) can be checked and only those in the 5' and 3' orientation with respect to the first phaseolin gene are used, for additional insertions. Because only the 3' BamHI site was retained (the BglII/BamHI ligated site is not digestible by either enzyme) this step could be repeated any number of times, depending on plasmid stability and ability to still transform E.coli and Agrobacteria. This procedure was repeated to obtain as many as four phaseolin gene inserts, which were cloned using a Hindlll and BamHI digest into the binary plasmid pGA482G. Having a series of these plasmids with different numbers of phaseolin genes (this can also be referred to as gene family transfer since a family of similar genes is transferred in a single event) will increase the level of storage proteins in seeds of transformed plants.
  • the purpose of this example is to incorporate a modified seed storage protein which encodes a higher percentage of sulfur-containing amino acids; such a gene is referred to as High Sulfur Storage
  • HSSP Protein
  • This gene is constructed so that it is developmentally expressed in the seeds of dicotyledonous plants; this has been accomplished by using the phaseolin promoter.
  • the modified gene must encode a substantial number of sulfur-containing amino acids.
  • Naturally occurring HSSP-genes can also be used.
  • the two best naturally occurring HSSP-genes are the beta zein gene (15 kD) (Pedersen et al (1986) J. Biol. Chem. 201:6279) and the Brazil nut protein
  • any other natural or synthetic gene derivative of an HSSP-gene can be used for the improvement of the nutritional value of seeds.
  • the construction of the zein derivative HSSP-gene uses the phaseolin gene promoter from clone pPv8.8-Bg [constructed by doing sight specific modification of pPv8.8g.
  • the BglII to Xbal fragment for pPV8.8g was cloned into M13mp 17 (commercially available) to obtain clone as 13mpl8PVl.6. This was then used to produce single- stranded DNA which was annealed to an oligomer (30 residues) which contained a two-base pair change from the original phaseolin promoter region.
  • the sequence of the oligomer was 5'CATCATAGTAGATCTAGTATTGAATATGAG-3' (opposite to coding strain).
  • the modified clone ml3 mpl81.6 30.12.3 was isolated and DNA was isolated. From the isolated DNA an Ncol to Xbal fragment was removed and cloned into Ncol and the partial XbaI digested p 8.8g.
  • the new clone containing the phaseolin promoter on a 800 bp Bgl II to Bgl II fragment was designated p Pv8.8g Bg.] to ensure proper expression and at a level expected for a seed storage protein, and the beta-zein clone pZGlSRX (Pedersen et al., ibid).
  • phaseolin promoter was made accessible by a site specific mutation at position -7 which resulted in a Bglll site, thus the phaseolin promoter could be removed after a Bglll digest as an 800 bp fragment. This fragment was subcloned into the BamHI site of pUC18 (available from commercial sources), yielding a plasmid designate pUC-Pvpro.
  • the beta-zein structural gene, including signal peptide, coding region, and Poly (A) addition signal was removed from plasmid pZG15EX (available from B.
  • This new binary plasmid is referred to as pGA482G-Phas-zein (see Chart 2) and it was transferred into Agrobacterium strains: A208, C58, LBA4404, C58Z707, and A4RS which in turn can be used to produce transformed plants in accordance with the method of this invention.
  • a phase zein construction similar to that described above has been transferred into dicotyledonous plants and its developmental expression in the seeds of the transformed plant has been observed; see Hoffman et al. (1987) EMBO J. 6:3213. Additional modification has been made to a Phas-zein gene construction.
  • the purpose of this example is to generate a construction for the expression of a plant virus coat protein gene which, when expressed in a dicotyledonous plant, results in reduced symptoms or resistance to later infections by that virus (see report by Powell-Abel et al. (1986) Science 232:738).
  • Viral coat proteins are isolated from any number of plant virus classes (tobamo, cucumo, poty, tobra, AMV, etc.) and they are expressed constitutively in plants after the attachment of the CaMV 35S promoter.
  • a plant poly (A) signal is added to the 3' region to ensure proper expression.
  • a clone containing any specific viral coat protein gene can be obtained for both plant DNA and RNA viruses.
  • This poly (A) region was used to anneal an aligo dT primer which was used to prime the synthesis of single-stranded (SS) cDNA using reverse transriptos and appropriate buffer of CMV-C SS-cDNA, double-stranded cDNA was synthesized by adding RNaso H to remove the RNA from the duplex and the second strand was made by adding E. coli DNP polymerase I (Klenow fragment) and the appropriate buffer. After synthesis of CMA-C ds-DNA, it was E. coli methylated using Eco RI methylase and Eco methylent buffer, thus protecting all internal Eco RI sites in the CMV-C ds-cDNA molecules.
  • the CMV-C ds-cDNA molecules were treated again with E coli polymorse I (Klenow fragment) to ensure that all ends (5' and 3') were flush, then these molecules were ligated to Eco RI linkers using T4-Ligase. After ligation the CMV-C ds-cDNA molecules were separated from contaminating linker by size fractionation on a GYOG column (1cm X 30cm). The fraction containing the majority of the CMV-C ds-cDNA molecules was EtOH precipitated, followed by resuspension in 10 ⁇ g of H20.
  • CiMV constitutive cauliflower mosaic virus
  • Attachment of the constitutive cauliflower mosaic virus (CaMV) 35S promoter was done by first doing a partial AccI and complete EcoRI digests of clone pCMV9.9 which was obtained by cloning the Eco RI insert from Lambda GT11-CMV9.9 into EcoRI cut puc 19 (commercially available). The 1100 bp CMV-C coat protein gene fragment was removed, both ends were blunted, and this fragment was cloned into the jjmal site of pDH51 (Pietrzak et al. (1986). fiuc. Acids Res. 14:5857) which is available from A.T.
  • this plant expressible CMV-C coat protein gene was removed from clone pDH51/CP19 by an EcoRI digest and the 1800 bp fragment was cloned into pUCl813 (which contains more restriction enzyme sites and is available from Dr. R. Kay, Washington State University, Pullman, Washington. The resulting clone, pUCl813/CP19, was then partially digested with Hindlll and the 1800 bp fragment was cloned into the binary vector pGA482 to obtain the new clone, pGA482/CPl9H (see Chart 3).
  • This binary plasmid, or its derivatives can be transferred into Agrobacterium strains: A208, C58, LBA4404, C58Z707, A4RS, A4RS(pRiB28b) and others.
  • this plant expressible CMV-C coat protein gene (or any other plant virus coat protein gene) can be transferred into a dicotyledonous plant species such as, cucumber, squash, melon, zucchini, pepper, etc.
  • the development of these new cultivars are useful because of their resistance to infections by specific virus or viruses (if more than one virus coat protein gene construction is transferred to a single plant).
  • the purpose of this example is to illustrate how to generate plant expressible genes which allow a plant to be resistant to specific classes of herbicides. Such plants are useful for many reasons; (i) herbicides normally lethal can be used, and (ii) different crops can be used in close rotations on soil which may contain residual amounts of a previously used herbicide that is normally lethal to the second crop.
  • Two genes of interest are mutant derivatives (derived from plant or bacterial sources) of the aceto ⁇ lactate synthase (ALS) gene which are not sensistive to chlorsulfuron and sulfometuron methyl herbicides (Falco et al., (1985) Biotech. Plant Sci. Academic Press, Inc.
  • EPSPS enolpyruvylshikimate-3-phosphate synthase
  • a gene which encodes an important enzyme which is either resistant to or detoxifies a specific herbicide is cloned downstream from a plant active promoter, such as: CaMV 35S, ribulose-1,5-bisphosphate carboxylase small subunit gene, or other strong plant gene promoter and upstream from a plant gene poly (A) signal sequence, see Chart 4.
  • This gene is then be cloned into an Agrobacterium-derived vector (either binary or cis) and using the above-described plant transformation method, such a gene is be transferred into many dicotyledonous plant species, such as: soybean, common bean, peppers, melons, etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Botany (AREA)
  • Environmental Sciences (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A non-tissue culture process using Agrobacterium-mediated vectors to produce transgenic plants from seeds of such plants as the common bean and soybean.

Description

AGROBACTERIUM MEDIATED TRANSFORMATION OF GERMINATING PLANT SEEDS FIELD OF INVENTION This invention relates to a process for transforming the germinating seed of a plant and the use of said process to produce transformed plants, particularly dicotyledonous plants.
BACKGROUND OF THE INVENTION The development of single gene transfer techniques for plant species is of great interest and value to plant breeders because it can be used for the rapid transfer of beneficial genetic traits to plants. Numerous methods have been developed for transferring genes into plant tissues; Agrobacterium-mediated transfer (Murai et al.. 1983; Fraley et al., 1983), direct DNA uptake (Paszkowski et al., 1984; Potrykus et al., 1985), microinjection (Crossway et al., 1986), high-velocity microprojectiles (Klein et al., 1987) and electroporation (Fromm et al., 1985; Fromm et al., 1986). A general problem with most of these gene transfer techniques is that the transformed tissues, either leaf pieces or cellular protoplast, must be subjected to some regeneration steps which require a considerable amount of time before a whole plant can be obtained. This process is further complicated because tissue culture procedures have not been established for many crop species. In most cases, gene transfers into crop species have been limited to transformed callus, not whole crop plants. In addition, tissue culture procedures can result in rearrangement of the inserted DNA; or somatic mutations may occur and result in the loss or alteration of desirable genetic traits accumulated by the expertise of many years of plant breeding.
Agrobacterium-mediated gene transfers are by far the most widely used gene transfer techniques, but the use of Agrobacterium strains may be limited because they do not efficiently infect monocotyledonous cereal crop species. However, recent reports (Hooykaas-Van Slogteren et al., 1984; Hernalsteens et al., 1984; Graves and Goldman, 1986; Grimsley et al., 1987; Schafer et al., 1987; Bytebier et al., 1987) suggest that conditions exist whereby Agrobacterium strains can bind to monocotyledonous plant cells and transfer their T-DNA regions into these cells. Interestingly, the report by Graves and Goldman (1986) suggests that Agrobacteria can infect scutellar and mesocotyl cells of germinating corn (Zea mays) seeds and that the resulting plants are transformed, although these transformed plants will be sectored. This technique suggests, that Agrobacterium-mediated gene transfer can be accomplished without the need of any tissue culture intermediate steps. Additional support for the transformation of mesocotyl cells of germinating seeds was obtained by Feldmann and Marks (1987) as they were able to obtain G418 resistant Arabidopsis thaliana plants by co-cultivating germinating seeds with Agrobacteria containing a binary plasmid with a plant expressible neomycin phosphotransferase (NPT) II gene in its T-DNA region.
The development of gene transfer techniques for leguminous plants is of commercial interest because it facilitates the development of new cultivars with improved disease resistance, tolerance to specific herbicides and increased nutritional value. Unfortunately, even though these dicotyledonous species are susceptible to Agrobacterium infections (Facciotti et al., 1985; Owens and Cress, 1985; Byrne et al., 1987), its use for transformation is limited due to the lack of available and efficient regeneration procedures, especially for transformed tissues. Extension of this technique to germinating seed of leguminous plants such as Phaseolus vulgaris., the common bean, is of great importance because regeneration procedures are not available, let alone the regeneration of transformed undifferentiated tissues.
The development of simple, non-tissue culture dependent methods for transfer, stable integration, and sexual transmission of genetic material into plant species is of great interest and importance. Reports from Graves and Goldman (1986) and Feldmann and Marks (1987) present evidence that transformed whole plants can be obtained via Agrobacterium-mediated transformation of the mesocotyl cells of germinating seeds.
The process of this invention represents (1) an improvement of the Graves and Goldman (1986) technique for the transformation of the seeds of monocotyledous plants and (2) its extension to dicotyledonous plants. INFORMATION DISCLOSURE
An G, Watson et al., (1985) New cloning vehicles for transformation of higher plants. EMBO J. 4:277-284.
Byrne M.C. et al., (1987) Strain and cultivar specificity in the Agrobacterium- soybean interaction. Plant Cell Tissue and Organ Culture 8: 3-15.
Bytebier B. et al., (1987) T-DNA organization in tumor cultures and transgenic plants of the monocotyledon Asparagus officinalis. Proc. Natl. Acad. Sci. USA 84: 5345-5349.
Chee P. P. et al., (1986) Expression of a bean storage protein "phaseolin minigene" in foreign plant tissues. Gene 41: 47-57.
Crossway A. et al., (1986) Integration of foreign DNA following microinjection of tobacco mesophyll protoplasts. Mol Gen Genet 202:179-185.
Facciotti D. et al., 1985) Light-indueible expression of a chimeric gene in soybean tissue transformed with Agrobacterium Biotechnology 3:241-246.
Feldmann K. A. et al., (1987) Agrobacterium-mediated transfor- mation of germinating seeds of Arabidopsis thaliana: A non-tissue culture approach. Mol Gen Gent 208:1-9.
Fraley R. T. et al., (1983) Expression of bacterial genes in plant cells. Proc Natl Acad Sci USA 80:4803-4807.
Fromm M. E. et al., (1986) Stable transformation of maize after gene transfer by electroporation. Nature 319:791-793.
Fromm M, et al., (1985) Expression of genes transferred into monocot and dicot plant cells by electroporation. Proc Natl Acad Sci USA 82:5824-5828.
Graves A. C. F. et al., (1986) The transformation of Zea mays seedlings with Agrobacterium tumefaciens. Plant Mol Biol 7:43-50.
Grimsley N. et al., (1987) Agrobacterium-mediated delivery of infectious maize streak virus into maize plants. Nature 325:177-179.
Hooykaas-Van Slogteren G.M.S. et al., (1984) Expression of Ti plasmid genes in monocotyledonous plants infected with Agrobacterium tumefaciens. Nature 311:763-764.
Hernalsteens J.P., et al, (1984) An Agrobacterium-transformed cell culture from the monocot Asparagus officinalis. EMBO J 3:3039-3044.
Jefferson (1986) B-Glucuronolose from Escherichia coli as a gene fusion marker. Proc. Natl. Acad. Sci., USA 83:8447-8451.
Klein T.M. et al.; (1987). High-velocity microprojectiles for delivering nucleic acids into living cells. Nature 327:70-73.
Murai N. et al., (1983) Phaseolin Gene from Bean is Expressed after transfer to Sunflower via Tumor-inducing Plasmid Vectors. Science 222:476-482.
Owens L.D. et al., (1985) Genotypic variability of soybean response to Agrobacterium strains harboring the Ti or Ri plasmids. Plant Physiol 77:87-94.
Paszkowski J. et al., (1984) Direct gene transfer to plants. EMBO J 3:2717-2722.
Pedersen K. et al., (1986) Sequence analysis and characterization of a maize gene encoding a high-sulfur zein protein of MW 15,000. J. Biol Chem 261:6279-6284.
Potrykus I. et al., (1985) Direct gene transfer to cells of a graminaceous monocot. Mol Gen Genet 199:183-188.
Reiss B. et al., (1984). A new sensitive method for qualitative and quantitative assay of neomycin phosphotransferase in crude cell extracts. Gene 30:211-218.
Schafer W. et al., (1987). T-DNA integration and expression in a monocot crop plant after induction of Agrobacterium. Nature 328:539-532.
Slightom J.L. et al,, (1983). Complete nucleotide sequence of a French bean storage protein gene. Phaseolin. Proc Natl Acad Sci USA 80:1897-1901.
A non-tissue culture approach for preparing transformed arabidopsis thaliana seeds is described by Feldmann and Marks, Mol. Gen. Genet. (1987) 208:19. However, to the inventors' knowledge the application of non-tissue culture transfer has not been successfully applied to leguminous plants and other large seed dicots such as soybean, the common bean, squash, zucchini, peppers, and others.
SUMMARY OF THE INVENTION The present invention provides : A process for producing a transgenic plant which comprises:
(a) germinating a seed of a plant;
(b) inoculating the meristematic or mesocotyl cells produced during germination, prior to their differentiation, with a virulent or non-virulent Agrobacterium strain containing a transferable gene in an Agrobacterium derived vector; and
(c) allowing the cells to differentiate into mature plants, with the proviso that the plant cannot be from the family Arabidopsis thaliana. The time of infecting germinating P. vulgaris seed after germination with the Agrobacterium-based vectors- has been found to be critical. The length of time the seeds are allowed tc germinate prior to Agrobacteria infection will greatly affect the ability of the Agrobacteria to infect meristematic cells, because the amount of vascular tissue is rapidly increasing as differentiation proceeds. However, seed germination must take place in order to have physical access to the mesocotyl region. Therefore a preferred manner of practicing the invention is to conduct the inoculation step within 16 to 96, preferably 24 to 48, hours of germination. To determine the optimum time for infecting germinating seeds, inoculations with virulent Agrobacterium strain A208 , were done at various times after initiating germination, between 6 to 96 hours. Successful transformation was scored by gall formation on the developing seedlings, the results of inoculating 50 seeds for each time interval is presented in Table I. Seeds allowed to germinate between 24 to 48 hours were found to be the most susceptible to Agrobacterium infections. Between 70% to 80% of these inoculated seeds gave rise to seedlings with galls formed either on the hypocotyl, epicotyl, cotyledonary node, or distributed throughout the base of the plant. A preferred method of inoculation is with a virulent or non-virulent Agrobacterium strain containing a transferable DNA cis or trans plasmid
A particularly preferred manner of practicing the process on dicots involves removing one of the cotyledons prior to inoculation. This step increases access of the strain to the mesocotyl region wherein the meristematic cells are generated.
The method of this invention is simple, rapid, avoids the use of any tissue culture techniques, and transformed plants can be obtained directly. Also provided are:
Transgenic plants prepared by the process of this invention. Preferred are dicotyledonous transgenic plants. Especially preferred are dicotyldonous plants of the family leguminoseae. such as phaseolus vulgaris and Glycinus max. DESCRIPTION OF THE PREFERRED EMBODIMENT
Germinating seeds are inoculated with either virulent or non- virulent Agrobacterium tumefacien or Agrobacterium rhizogenes strains which contain the binary plasmid pGA472 or PGA482 or their deriv atives. Both are available from Dr. G. An, Washington State University, Pullman, WA. This binary plasmid encodes a plant expressible NPT II gene within its T-DNA region and their derivatives contain genes that will convey useful traits to transformed species. Most plants resulting from seeds inoculated with virulent Agrobacterium strains, which also contained the binary plasmid, developed typical crown galls. However, NPT II activity was found in the leaves of some inoculated whole plants, indicating that the binary T-DNA region was also transferred. Transfer of the binary T-DNA region was also accomplished by using avirulent strains of A. tumefaciens or rhizogenes. Results presented here show that 1.6% of the P . vulgaris and about 1% of the Glycine Max (soybean) plants were transformed, with transformation being determined by the presence of NPT II enzyme activity. Seeds of Phaseolus vulgaris cv. Olathe or Glvcine max (cV.A0949) were surface sterilized with 15% Clorox for 10 minutes, followed by 4-5 rinses with distilled water and then placed on moistened paper towels in a temperature controlled Percival incubator at 28ºC. and allowed to germinate for various times, 16 to 96 hours. Seed coats were removed and the decoated seeds were opened in halves (that is how cotyledons were removed from the main seed body). The mesocotyl region of the germinating seeds, with their plummule still attached, were infected with an overnight liquid culture of various Agrobacterium strains by using an Eppendorf pipetter fitted with a 27 1/2 gauge needle. Seeds were infected with virulent or avirulent A. tumefaciens strains (A208, C58, C58z707 and A208/phas-zein) or A. rhizogenes strains [A4RS and A4RS(pR:B278b)pu3.3c-1]. The common A. tumefaciens and A. rhizogenes strains are available from ATCC, 12301 Parklawn Drive, Rockville, MD. The disarmed A. rhizogenes strain RS(pRiB278b) has been described by Vilaine and Casse-Delbart (1987) Mol. Gen. Genet., 206,17 and is available from Dr. F. Casse-Delbart, C.N.R.A., Routede Saint Cyr, F78000, Versailles, France. The disarmed A. tumefaciens. strain C582707 is available from Dr. A. G. Hepburn, University of Illinois, Urbana, IL. Inoculated seeds were then placed on moistened paper towels in petri dishes and incubated at 28"C. After four days these seedlings were transformed to soil and grown to maturity in the greenhouse. Plants infected with virulent strains of A. tumefaciens were scored for efficiency of gall formation as a function of germination time. NPT II Enzvme Activity
NPT II enzyme activity was detected by the in situ gel assay as reported by Reiss et al. (1984). Briefly, 100 mg. of a leaf tissue was mixed with 20 ml . of extraction buffer in a 1.5 ml. Eppendorf tube. Tissue samples were macerated with a Konte pestle and centrifuged for 20 minutes at 4°C. A 35 μl aliquot of the supernatant solutions was electrophoresed on a non-denaturing 10% polyacrylamide gel. The gel was overlaid with a 1% agarose gel containing 67 mM. tris-maleate (pH 7.1), 42 mM. MgCl2. 400 mM NH4CI, 20 μg kanamycin sulfate and 200 μCi gamma- [32p]ATP. After incubating for 30 minutes at room temperature, the agarose gel was blotted onto Whatman P81 phosphocellulose paper overnight. The P81 paper was removed, washed several times with hot water (80°C.) and autoradiographed. The following examples utilize many techniques well known and accessible to those skilled in the arts of molecular biology and manipulation of Agrobacterium strains and plasmids (virulent, avirulent, cis- or trans- configurations). Enzymes are obtained from commercial sources and are used according to the vendor's recommendations or other variations known to the art. Reagents, buffers and culture conditions are also known to those in the art. General references containing such standard techniques include the following: R. Wu, ed. (1979) Meth. Enzvmol. Vol. 68; J. H. Miller (1972) Experiments in Molecular Genetics: T. Maniatis et al. (1982) Molecular Cloning: A Laboratory Manual; and D. M. Glover, ed. (1985) DNA Cloning Vol. II, all of which are incorporated by reference.
The purpose of these examples is to show that gene constructions exist, either constructed by us or others, which when transferred, integrated, and expressed in a plant will convey a useful trait to that plant. Example 1.
Germinating P. vulgaris and G. max seeds were inoculated about 24 hours after germination with virulent and avirulent Agrobacterium strains which contained modified pGA482G [constructed by clearing the SalF fragment from pWP866 which contains the gene for gentamycin-(3)- N-acetyl-benferose III, and is available from W. Piepersberg, P-8080, Munich, Federal Republic of Germany, into one of the SaIl sites in pGA482, based binary vector constructions pPhas-zein [which contains the corn beta-zein gene (Pedersen et al., 1987 and is available from Dr. B. Larkins, Purdue University, West Lafayette, IN) transcriptionally linked to the P. vulgaris seed storage protein gene promotor (Slightom et al., 1983) or pu3.3c-1 [which contains the phaseolin minigene construction (Chee et al., 1985) and is available from Agrigenetics Corp, Madison, WI]. Physical maps of these binary plasmids are presented in Chart 2.
Transfer and expression of the plant expressible NPT II gene contained within the T-DNA region of pGA482G (An et al., 1984) was determined by removing two to three young leaves (usually obtained 10 inches or more above the wound site resulting from inoculating the germinating seeds), extracting the soluble proteins and testing for NPT II activity. From a total of 695 plants tested only 11 plants showed NPT II activity in these protein extracts. They are listed in Table II and the NPT II positive results are shown in Chart 2. About 1.6% of the surviving inoculated seeds show NPT II activity, suggesting that the T-DNA region of the binary plasmid pGA482G is integrated in the genome of these P. vulgaris plants.
Other procedures, well known to those skilled in the art, such as microinjection and high-velocity microprojectiles, can be used to transfer DNAs into the mesocotyl region and that transformed plants should result.
TABLE I
Frequency of Gall Formation on Seedlings Inoculated
With the Agrobacterium Strain A208
Germination Periods Frequuncy of Gall Formation
6 hours 0
12 hours 0
24 hours 80
36 hours 70
48 hours 40
72 hours 10
90 hours 10
TABLE II
NPT II Positive Transformed Plants
Plant Number Binary Construction Gall
40 C58/phas-zein +
41 C58/phas-zein +
46 C58/phas-zein +
61 C58/phas-zein -
65 C58/phas-zein -
151 C58/phas-zein +
258 A4RS(pR:B278b)pu3.3c-1 -
269 A4RS(pR:B278b)pu3.3c-1 -
296 A4RS(PR:B278b)pu3.3c-1 -
470 A208/phas-zein -
552 C58Z707/phas-zein -
Example 2
Construction of a micro-Ti plasmid for the expression of a phaseolin mini-gene. The transfer and expression of this gene will increase the level of seed storage protein in the transformed plant. 2.1
Using the P. vulgaris seed storage protein gene, phaseolin, and its cDNA counterpart a mutant phaseolin gene lacking its five introns was constructed. This mutant phaseolin gene (phas-minigene) retains it natural 5' and 3' plant-regulatory sequences and the construction of this plasmid (pPv3.3-cDNA) has been described by Chee et al. (1986) Gene 41:47 and Cramer et al. (1985) Proc. Natl. Acad. Sci. 82; 334 and is available from Agrigenetics Corp. Madison, WI. Plasmid pPv3.3-cDNA was subjected to restriction enzyme digests, BamHI and HindIII and a 3.6 kb fragment was removed and cloned into BglII and HindIII sites of the binary vector pGA482 (An et al. (1985) EMBO. J. 4:277). This construction places this mutant phaseolin gene within the right and left borders of the binary plasmid, now referred to as p/i3.3c-l, and along side of the plant expressible NPT II gene which is used for selection and identification of transformed plants. The structure of binary plasmid pu3.3c-l is shown in Chart 1. 2.2 Use of pu3.3c-l
This binary plasmid has to be transferred into various Agrobacterium strains, i.e. A208, C58, C58:707, LBA4404 and A4RS, etc. The method described here can be used to transfer the binary plasmid pμ3.3c-l into various plant species (e.g., common bean, soybean and other large seeded plants). In addition, multiple copies of the phaseolin minigene can be placed into the binary plasmid by subcloning the NcoI to BamHI fragment (3 kb fragment) frompPv3.3-CDNA into NcoInd BamHI digested clone pPr 8.8 g (available from J. Slightom, The Upjohn Company, Kalamazoo, MI) which replaces the genomic part with the CDNA region of pPV3.3-cDNA. This cloning experiment results in obtaining subclone pPv8.3-cDNA which contains an upstream BglII site (Slightom, et al. (1983) Proc. Natl, Acad. Sci.. 80:1897) which allows for the isolation of a BglII-BamHI 3.3,5 kb fragment which was recloned into the BamHI digested plasmid pPv3.3-cDNA. The orientation of the new phaseolin insert(s) can be checked and only those in the 5' and 3' orientation with respect to the first phaseolin gene are used, for additional insertions. Because only the 3' BamHI site was retained (the BglII/BamHI ligated site is not digestible by either enzyme) this step could be repeated any number of times, depending on plasmid stability and ability to still transform E.coli and Agrobacteria. This procedure was repeated to obtain as many as four phaseolin gene inserts, which were cloned using a Hindlll and BamHI digest into the binary plasmid pGA482G. Having a series of these plasmids with different numbers of phaseolin genes (this can also be referred to as gene family transfer since a family of similar genes is transferred in a single event) will increase the level of storage proteins in seeds of transformed plants. Example 3
The purpose of this example is to incorporate a modified seed storage protein which encodes a higher percentage of sulfur-containing amino acids; such a gene is referred to as High Sulfur Storage
Protein (HSSP)-gene. This gene is constructed so that it is developmentally expressed in the seeds of dicotyledonous plants; this has been accomplished by using the phaseolin promoter. The modified gene must encode a substantial number of sulfur-containing amino acids. Naturally occurring HSSP-genes can also be used. The two best naturally occurring HSSP-genes are the beta zein gene (15 kD) (Pedersen et al (1986) J. Biol. Chem. 201:6279) and the Brazil nut protein
(Altenbach et al. (1987) Plant Mol. Bio. 8:239). However, any other natural or synthetic gene derivative of an HSSP-gene can be used for the improvement of the nutritional value of seeds.
3.1 Construction of a HSSP-gene
The construction of the zein derivative HSSP-gene uses the phaseolin gene promoter from clone pPv8.8-Bg [constructed by doing sight specific modification of pPv8.8g. The BglII to Xbal fragment for pPV8.8g was cloned into M13mp 17 (commercially available) to obtain clone as 13mpl8PVl.6. This was then used to produce single- stranded DNA which was annealed to an oligomer (30 residues) which contained a two-base pair change from the original phaseolin promoter region. The sequence of the oligomer was 5'CATCATAGTAGATCTAGTATTGAATATGAG-3' (opposite to coding strain). After annealing DNA polymerase I (Klenow fragment) was added and the remaining opposite strand of M13MP18pvl.6 was synthesized. The mutant M13 clone, containing a new Bgl site 7 bp from the translation start site (Slightom et al, 1983, ibid) of the phaseloin gene, was screened using the 32p-labeled oligomer and differential., temperature hybridization. Cloned candidates were further analyzed by doing Bgl II digestions and agarose gel electrophoresis to identify particular clones containing the extra Bgl II. site, the appearance of the Bgl II to Bgl II 800 bp fragment. The modified clone ml3 mpl81.6 30.12.3 was isolated and DNA was isolated. From the isolated DNA an Ncol to Xbal fragment was removed and cloned into Ncol and the partial XbaI digested p 8.8g. The new clone containing the phaseolin promoter on a 800 bp Bgl II to Bgl II fragment was designated p Pv8.8g Bg.] to ensure proper expression and at a level expected for a seed storage protein, and the beta-zein clone pZGlSRX (Pedersen et al., ibid). The phaseolin promoter was made accessible by a site specific mutation at position -7 which resulted in a Bglll site, thus the phaseolin promoter could be removed after a Bglll digest as an 800 bp fragment. This fragment was subcloned into the BamHI site of pUC18 (available from commercial sources), yielding a plasmid designate pUC-Pvpro. The beta-zein structural gene, including signal peptide, coding region, and Poly (A) addition signal was removed from plasmid pZG15EX (available from B. Larkins, Purdue University, West Lafayette, IN) after a TagI digestion and this fragment was cloned into the Accl site of pUC-Pvpro, yielding clone pUC-Phas-zein. This Phaszein gene was removed by digestion with Hindlll and EcoRI and this fragment was cloned into the binary vector pGA482G, which had previously been digested with HindIII and EcoRI. This new binary plasmid is referred to as pGA482G-Phas-zein (see Chart 2) and it was transferred into Agrobacterium strains: A208, C58, LBA4404, C58Z707, and A4RS which in turn can be used to produce transformed plants in accordance with the method of this invention. A phase zein construction similar to that described above has been transferred into dicotyledonous plants and its developmental expression in the seeds of the transformed plant has been observed; see Hoffman et al. (1987) EMBO J. 6:3213. Additional modification has been made to a Phas-zein gene construction. These modifications include the ligation of a BglII linker onto its 5' -end and a BamHI linker onto its 3'-end which allows the construction of multiple copies of the phase zein gene as described above for the phaseolin minigene. This allows for the transfer of a HSSP-gene multigene family into a plant species by a single transformation event and the expression of higher levels of the HSSP-gene product. This leads to the development of dicotyledonous plant varieties which are nutritionally improved, such as common bean, soybean and other large seeded plants.
Example 4 Transfer of Viral Resistance
The purpose of this example is to generate a construction for the expression of a plant virus coat protein gene which, when expressed in a dicotyledonous plant, results in reduced symptoms or resistance to later infections by that virus (see report by Powell-Abel et al. (1986) Science 232:738). Viral coat proteins are isolated from any number of plant virus classes (tobamo, cucumo, poty, tobra, AMV, etc.) and they are expressed constitutively in plants after the attachment of the CaMV 35S promoter. In addition, a plant poly (A) signal is added to the 3' region to ensure proper expression.
A clone containing any specific viral coat protein gene can be obtained for both plant DNA and RNA viruses. Such is the case for cucumber mosaic virus strain C (CMV-C); its RNA genome was copied into double-stranded cDNA and the coat protein gene was isolated and characterized as follows. A residues were added to the 3' end of CMV-C total RaH, using E. coli polyadenylose. This poly (A) region was used to anneal an aligo dT primer which was used to prime the synthesis of single-stranded (SS) cDNA using reverse transriptos and appropriate buffer of CMV-C SS-cDNA, double-stranded cDNA was synthesized by adding RNaso H to remove the RNA from the duplex and the second strand was made by adding E. coli DNP polymerase I (Klenow fragment) and the appropriate buffer. After synthesis of CMA-C ds-DNA, it was E. coli methylated using Eco RI methylase and Eco methylent buffer, thus protecting all internal Eco RI sites in the CMV-C ds-cDNA molecules. After Eco methylation the CMV-C ds-cDNA molecules were treated again with E coli polymorse I (Klenow fragment) to ensure that all ends (5' and 3') were flush, then these molecules were ligated to Eco RI linkers using T4-Ligase. After ligation the CMV-C ds-cDNA molecules were separated from contaminating linker by size fractionation on a GYOG column (1cm X 30cm). The fraction containing the majority of the CMV-C ds-cDNA molecules was EtOH precipitated, followed by resuspension in 10 μg of H20. About 100 μg of these Eco RI linked CMV-C ds-cDNA molecules were removed and mixed with lμg of λ gT11 arms (commercially available) and ligated together using T4 ligase. The recombinant GT 11-CMV-C were plated using E. coli Up50supF as host and these plates (10-4 clones) were screened for clones containing CMV-C coat protein gene coding region using p-labeled CMV-whiteleaf SS-cDNA as probe. From this screening, a clone, λ GT11-CMV9.9 was isolated. It contained an EcoRI insert of 1400 base pair, enough to encode the complete CMV coat protein. This CMV coat protein gene can be expressed in plant tissues once a plant-active promoter and poly (A) signal are attached to its 5' and 3' regions, respectively. The scheme to accomplish this is shown in Chart 3.
Attachment of the constitutive cauliflower mosaic virus (CaMV) 35S promoter was done by first doing a partial AccI and complete EcoRI digests of clone pCMV9.9 which was obtained by cloning the Eco RI insert from Lambda GT11-CMV9.9 into EcoRI cut puc 19 (commercially available). The 1100 bp CMV-C coat protein gene fragment was removed, both ends were blunted, and this fragment was cloned into the jjmal site of pDH51 (Pietrzak et al. (1986). fiuc. Acids Res. 14:5857) which is available from A.T. Mohn, Friedrick Mieschen Institut, Basel, Switzerland to obtain clone pDH51/cP19.. This positioned the CMV-C coat protein gene downstream of the CaMV 35S promoter and upstream from the CaMV poly (A) signal sequence. To ensure a high level of expression other poly (A) signal sequences (which may function better than the CaMV 35S poly (A) signal) can be attached, such as the poly (A) signal from the seed storage protein gene phaseolin (Slightom et al. (1983) Proc. Natl. Acad. Sci. 80:1897). To facilitate engineering, this plant expressible CMV-C coat protein gene was removed from clone pDH51/CP19 by an EcoRI digest and the 1800 bp fragment was cloned into pUCl813 (which contains more restriction enzyme sites and is available from Dr. R. Kay, Washington State University, Pullman, Washington. The resulting clone, pUCl813/CP19, was then partially digested with Hindlll and the 1800 bp fragment was cloned into the binary vector pGA482 to obtain the new clone, pGA482/CPl9H (see Chart 3). This binary plasmid, or its derivatives, can be transferred into Agrobacterium strains: A208, C58, LBA4404, C58Z707, A4RS, A4RS(pRiB28b) and others. Using the transformation method of this invention, this plant expressible CMV-C coat protein gene (or any other plant virus coat protein gene) can be transferred into a dicotyledonous plant species such as, cucumber, squash, melon, zucchini, pepper, etc. The development of these new cultivars are useful because of their resistance to infections by specific virus or viruses (if more than one virus coat protein gene construction is transferred to a single plant). Example 5 Transfer of Herbicide Resistance
The purpose of this example is to illustrate how to generate plant expressible genes which allow a plant to be resistant to specific classes of herbicides. Such plants are useful for many reasons; (i) herbicides normally lethal can be used, and (ii) different crops can be used in close rotations on soil which may contain residual amounts of a previously used herbicide that is normally lethal to the second crop. Two genes of interest are mutant derivatives (derived from plant or bacterial sources) of the aceto¬lactate synthase (ALS) gene which are not sensistive to chlorsulfuron and sulfometuron methyl herbicides (Falco et al., (1985) Biotech. Plant Sci. Academic Press, Inc. page 313) and mutants of the gene encoding enolpyruvylshikimate-3-phosphate synthase (EPSPS) (Stalker et al, (1985) J. Biol. Chem., 260:4724) which are not sensitive to the herbicide glyphosate.
A gene which encodes an important enzyme which is either resistant to or detoxifies a specific herbicide is cloned downstream from a plant active promoter, such as: CaMV 35S, ribulose-1,5-bisphosphate carboxylase small subunit gene, or other strong plant gene promoter and upstream from a plant gene poly (A) signal sequence, see Chart 4. This gene is then be cloned into an Agrobacterium-derived vector (either binary or cis) and using the above-described plant transformation method, such a gene is be transferred into many dicotyledonous plant species, such as: soybean, common bean, peppers, melons, etc. Example 6 Transfer of Insect-Resistant Gene
In nature, numerous polypeptides exist which are toxic to insect pests. The best known protein toxins are those associated with different strains of Bacillus thuringiensis: for example, B. israelenis active against Diptera (mosquitoes and blackflies), B. thuringinensis active against Lepidoptera, and B. san diego active against Coleoptera. The toxi protein found in each of these bacteria is highly specific to insect pests; they are not toxic to other organisms. Thus the transfer and expression of genes encoding such toxic proteins in plants are beneficial in reducing insect damage without using chemical insecticides thereby avoiding risk to other organisms. The genes encoding many of these toxic proteins have been isolated and sequenced (Schnepf et al. (1985) J. Biol. Chem. , 260:6264; Waalwijk et al., (1985) Nucl. Acids Res., 13:8207; Sekar et al (1987) Proc. Natl. Acad. Sci.. 84:7036). The transfer of the B . thuringiensis toxic gene into tobacco and its usefulness in protecting the plant from insect damage has been reported (Vaeck et al. (1987) Nature 328:33). Thus, the combination of using the plant transformation system described here and plant expressible Bacillus toxin gene (see Chart 5) allows for the transfer of a useful trait to any dicotyledonous species for which tissue-culture based transformation systems are inefficient or have not been developed, such as: common bean, soybean, melon, cucumber, squash, zucchini, pepper, etc.
Figure imgf000020_0001
Figure imgf000020_0002
Figure imgf000020_0003
Figure imgf000021_0001
Figure imgf000021_0002

Claims

1. A process for producing a transgenic plant which comprises: (a) germinating a seed of a plant; (b) inoculating the meristematic or mesocotyl cells produced during germination, prior to their differentiation, with a virulent or non-virulent Agrobacterium strain containing a transferable gene in an Agrobacterium derived vector; and
(c) allowing the cells to differentiate into mature plants, with the proviso that the plant cannot be from the family Arabidopsis thaliana.
2. A process according to claim 1 wherein the vector is a plasmid adapted for either transfer in trans- or cis- configuration.
3. A process according to claim 2 wherein the the vector is a binary plasmid adapted for transfer in the trans configuration.
4. A process according to claim 3 wherein the plant is dicotyledonous.
5. A process according to claim 4 wherein one of the cotyledons is removed prior to inoculation.
6. A transgenic plant prepared by the process of claim 1.
7. A transgenic dicotyledonous plant according to claim 6.
8. A plant according to claim 7 wherein the plant is a member of the family leguminoseae.
9. A plant according to claim 8 wherein the plant is a soybean.
10. A plant according to claim 9 wherein the plant is common bean.
11. A plant according to claim 10 wherein the plant gene is the gene for phaseolin.
PCT/US1988/004464 1987-12-21 1988-12-16 Agrobacterium mediated transformation of germinating plant seeds WO1989005859A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AT8989900780T ATE105585T1 (en) 1987-12-21 1988-12-16 TRANSFORMATION OF GERMINATED PLANT SEEDS USING AGROBACTERIUM.
DE3889546T DE3889546T2 (en) 1987-12-21 1988-12-16 TRANSFORMATION OF Germinating PLANT SEEDS WITH THE HELP OF AGROBACTERIUM.
EP89900780A EP0397687B1 (en) 1987-12-21 1988-12-16 Agrobacterium mediated transformation of germinating plant seeds
DK126690A DK126690A (en) 1987-12-21 1990-05-22 TRANSGENIC PLANT AND PROCEDURES FOR PRODUCING THEREOF

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13565587A 1987-12-21 1987-12-21
US135,655 1987-12-21

Publications (1)

Publication Number Publication Date
WO1989005859A1 true WO1989005859A1 (en) 1989-06-29

Family

ID=22469055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/004464 WO1989005859A1 (en) 1987-12-21 1988-12-16 Agrobacterium mediated transformation of germinating plant seeds

Country Status (9)

Country Link
US (2) US5169770A (en)
EP (1) EP0397687B1 (en)
JP (1) JPH04501201A (en)
KR (1) KR0154872B1 (en)
AT (1) ATE105585T1 (en)
AU (2) AU633248B2 (en)
DE (1) DE3889546T2 (en)
DK (1) DK126690A (en)
WO (1) WO1989005859A1 (en)

Cited By (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004332A1 (en) * 1989-09-20 1991-04-04 The Upjohn Company Somatic embryogenesis of squash
EP0424047A1 (en) * 1989-10-17 1991-04-24 Pioneer Hi-Bred International, Inc. Tissue culture method for transformation of plant cells
WO1992006205A1 (en) * 1990-09-27 1992-04-16 Clovis Matton N.V. A process for the gene manipulation of plant cells, recombinant plasmids, recombinant bacteria, plants
US5543576A (en) * 1990-03-23 1996-08-06 Mogen International Production of enzymes in seeds and their use
US5593963A (en) * 1990-09-21 1997-01-14 Mogen International Expression of phytase in plants
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
WO2000037663A2 (en) * 1998-12-23 2000-06-29 The Samuel Roberts Noble Foundation, Inc. Plant transformation process
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6160201A (en) * 1993-07-09 2000-12-12 Seminis Vegetable Seeds, Inc. Lettuce infectious yellows virus genes
US6291643B1 (en) 1997-06-05 2001-09-18 Board Of Reports, The University Of Texas System Apaf-1 an activator of caspase-3
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
WO2002030463A2 (en) 2000-10-12 2002-04-18 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1236801A2 (en) * 2001-02-26 2002-09-04 The Agri-Biotechnology Research Center of Shanxi Method of agrobacterium mediated plant transformation through treatment of germinating seeds
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US6469144B1 (en) 1996-04-01 2002-10-22 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
US6555335B1 (en) 1999-12-30 2003-04-29 Genencor International, Inc. Xylanase from Trichoderma reesei , method for production thereof, and methods employing this enzyme
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
EP1382679A2 (en) 1995-09-08 2004-01-21 Genentech, Inc. Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists
US6727079B1 (en) 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
US6740739B1 (en) 1998-01-15 2004-05-25 Genentech, Inc. Substitutional variants of APO-2 ligand
US6746668B2 (en) 1996-01-09 2004-06-08 Genentech, Inc. Apo-2 ligand
US6764679B2 (en) 1997-09-18 2004-07-20 Genentech, Inc. Antibodies to DcR3 Polypeptide, a TNFR Homolog
US7033627B2 (en) 1990-03-23 2006-04-25 Syngenta Mogen B.V. Production of enzymes in seeds and their use
EP1666052A1 (en) 2000-02-16 2006-06-07 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
US7173115B2 (en) 2000-01-13 2007-02-06 Genentech, Inc. Stra6 polypeptides
EP1757701A1 (en) 1999-12-24 2007-02-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1820859A2 (en) 1998-12-22 2007-08-22 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP1865061A2 (en) 1998-05-15 2007-12-12 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP1895017A2 (en) 2002-10-03 2008-03-05 Genentech, Inc. Use of A33 antigens and JAM-IT
WO2008033890A2 (en) 2006-09-12 2008-03-20 Beth Israel Deaconess Medical Center, Inc. Compositions containing alpha-1-antitrypsin and methods for use
EP1944317A2 (en) 2000-09-01 2008-07-16 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1953173A1 (en) 1999-06-15 2008-08-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
EP1958965A2 (en) 1997-08-25 2008-08-20 Genentech, Inc. Agonist antibodies to a musk receptor, and their therapeutic uses
EP1967587A1 (en) 1997-10-10 2008-09-10 Genentech, Inc. APO-3 Ligand
EP1992643A2 (en) 2001-06-20 2008-11-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1995321A2 (en) 2005-08-15 2008-11-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2002714A1 (en) 2005-11-21 2008-12-17 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2011886A2 (en) 2002-04-16 2009-01-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2014677A1 (en) 1997-11-21 2009-01-14 Genentech, Inc. A-33 related antigens and their pharmacological uses
EP2014298A2 (en) 2000-08-24 2009-01-14 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP2014675A1 (en) 2003-08-11 2009-01-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2014770A2 (en) 1997-10-29 2009-01-14 Genentech, Inc. WNT-1 Iinduced secreted polypeptide WISP-2
EP2033970A2 (en) 1997-10-29 2009-03-11 Genentech, Inc. WNT-1 inducible genes
EP2042597A1 (en) 2000-06-23 2009-04-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2050335A1 (en) 2006-02-17 2009-04-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2050762A2 (en) 1998-03-10 2009-04-22 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
EP2065467A2 (en) 2001-02-22 2009-06-03 Genentech, Inc. Anti-interferon-alpha antibodies
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2075253A1 (en) 2000-06-23 2009-07-01 Genentech, Inc. Compositions and methds for the diagnosis and treatment of disorders involving angiogensis
EP2075334A1 (en) 2000-06-23 2009-07-01 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and methods of use
EP2083079A1 (en) 1997-06-18 2009-07-29 Genentech, Inc. Apo-2DcR
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2083018A2 (en) 2003-04-16 2009-07-29 Genentech, Inc. Compositions and methods relating to STOP-1
EP2085096A2 (en) 2002-09-11 2009-08-05 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
EP2116551A1 (en) 2002-09-11 2009-11-11 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2143438A1 (en) 2001-09-18 2010-01-13 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2161283A1 (en) 2003-11-17 2010-03-10 Genentech, Inc. Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin
US7705195B2 (en) 2002-06-07 2010-04-27 Genentech, Inc. Screening method
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP2186402A1 (en) 2005-06-06 2010-05-19 Genentech, Inc. Knock-out animal models for novel genes and methods of use
EP2228446A1 (en) 1999-12-01 2010-09-15 Genentech, Inc. Secreted and transmembrane polypeptieds and nucleic acids encoding the same
EP2233149A1 (en) 2007-10-16 2010-09-29 ZymoGenetics, Inc. Combination of BLYS inhibition and anti-CD20 agents for treatment of autoimmune disease
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
EP2256134A1 (en) 2003-11-13 2010-12-01 Hanmi Pharmaceutical Co., Ltd. IgG Fc fragment for a drug carrier and method for the preparation thereof
EP2258848A1 (en) 1999-12-23 2010-12-08 Genentech, Inc. Il-17 homologous polypeptide and therapeutic uses thereof
EP2272868A2 (en) 2003-06-05 2011-01-12 Genentech, Inc. Combination therapy for B cell disorders
EP2277908A2 (en) 2003-07-08 2011-01-26 Genentech, Inc. IL-17A/F heterologous polypeptides, antibodies and therapeutic uses thereof
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
WO2011031397A1 (en) 2009-08-06 2011-03-17 Genentech, Inc. Method to improve virus removal in protein purification
EP2305823A1 (en) 2001-01-15 2011-04-06 Wista Laboratories Ltd. Materials and methods relating to protein aggregation in neurodegenerative disease
EP2308968A1 (en) 2002-11-26 2011-04-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2311960A2 (en) 2001-08-29 2011-04-20 Genentech, Inc. Bv8 nucleic acids and polypeptides with mitogenic activity
EP2311956A1 (en) 1999-06-28 2011-04-20 Genentech, Inc. Methods for making APO-2 ligand using divalent metal ions
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
EP2319929A1 (en) 1998-12-23 2011-05-11 Genentech, Inc. IL-1 related polypeptides
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
EP2322201A2 (en) 2002-10-29 2011-05-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2322165A1 (en) 2001-11-13 2011-05-18 Genentech, Inc. Apo2 ligand/TRAIL formulations
WO2011060246A2 (en) 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
WO2011066503A2 (en) 2009-11-30 2011-06-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2333069A2 (en) 1998-05-15 2011-06-15 Genentech, Inc. Therapeutic uses of IL-17 homologous polypeptides
EP2332956A1 (en) 2002-07-08 2011-06-15 Genentech, Inc. Antibody binding to PRO71238
EP2335725A1 (en) 2003-04-04 2011-06-22 Genentech, Inc. High concentration antibody and protein formulations
EP2348043A1 (en) 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
WO2011106297A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2364716A2 (en) 2002-11-08 2011-09-14 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
WO2011139985A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2388265A1 (en) 2002-02-22 2011-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2389951A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
WO2011150110A1 (en) 2010-05-25 2011-12-01 Genentech, Inc. Methods of purifying polypeptides
WO2012036884A2 (en) 2010-09-15 2012-03-22 Aligna Technologies, Inc. Bioproduction of aromatic chemicals from lignin-derived compounds
EP2436781A1 (en) 2007-02-22 2012-04-04 Genentech, Inc. Methods for detecting inflammatory bowel disease
EP2444409A2 (en) 2002-09-16 2012-04-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2450050A1 (en) 2006-11-29 2012-05-09 Genentech, Inc. IL-17A/F heterodimeric polypeptides and therapeutic uses thereof
US8217223B2 (en) 2004-06-16 2012-07-10 Basf Plant Science Gmbh Nucleic acid molecules encoding WRINKLED1-like polypeptides and methods of use in plants
EP2474557A2 (en) 2007-07-16 2012-07-11 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
EP2500438A2 (en) 2002-09-25 2012-09-19 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
EP2500032A1 (en) 2002-06-24 2012-09-19 Genentech, Inc. APO-2 ligand/trail variants and uses thereof
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
EP2526960A1 (en) 2003-03-12 2012-11-28 Genentech, Inc. Use of BV8 and/or EG-VEGF to promote hematopoiesis
EP2614839A2 (en) 2006-04-05 2013-07-17 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
US8535912B2 (en) 2009-10-15 2013-09-17 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
EP2641618A2 (en) 2007-07-16 2013-09-25 Genentech, Inc. Humanized anti-CD79B antibodies and immunoconjugates and methods of use
EP2657253A2 (en) 2008-01-31 2013-10-30 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
WO2013163606A1 (en) 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vascular endothelial growth factor antagonists and methods for their use
WO2014088934A1 (en) 2012-12-07 2014-06-12 Danisco Us Inc. Compositions and methods of use
WO2014088940A1 (en) 2012-12-07 2014-06-12 Danisco Us Inc. Compositions and methods of use
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
WO2014144911A2 (en) 2013-03-15 2014-09-18 Capon Daniel J Hybrid immunoglobulin containing non-peptidyl linkage
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
US9278131B2 (en) 2012-08-10 2016-03-08 Adocia Process for lowering the viscosity of highly concentrated protein solutions
EP3002295A1 (en) 2008-04-28 2016-04-06 Genentech, Inc. Humanized anti-factor d antibodies and uses thereof
WO2016054194A1 (en) 2014-09-30 2016-04-07 1/1Danisco Us Inc Compositions comprising beta-mannanase and methods of use
WO2016054168A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta mannanase and methods of use
WO2016054205A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta mannanase and methods of use
WO2016054185A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta-mannanase and methods of use
WO2016054176A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta-mannanase and methods of use
EP3026123A1 (en) 2006-04-27 2016-06-01 Klaritos, Inc. Method and kit for predicting antibody therapy
WO2016100825A1 (en) 2014-12-18 2016-06-23 Danisco Us Inc Engineered multifunctional enzymes and methods of use
WO2016100837A1 (en) 2014-12-18 2016-06-23 Danisco Us Inc Engineered multifunctional enzymes and methods of use
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP3208612A1 (en) 2008-04-09 2017-08-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP3284825A1 (en) 2006-11-02 2018-02-21 Daniel J. Capon Methods of producing hybrid polypeptides with moving parts
EP3332798A1 (en) 2010-08-31 2018-06-13 Generon (Shanghai) Corporation Ltd. Use of interleukin-22 in treating viral hepatitis
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
WO2019148020A1 (en) 2018-01-26 2019-08-01 Genentech, Inc. Compositions and methods of use
WO2019148026A1 (en) 2018-01-26 2019-08-01 Genentech, Inc. Il-22 fc fusion proteins and methods of use
WO2019165140A1 (en) 2018-02-21 2019-08-29 Genentech, Inc. DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
US10543169B2 (en) 2013-11-07 2020-01-28 Generon (Shanghai) Corporation Ltd. Use of IL-22 dimer in manufacture of a medicament for intravenous administration
EP3701971A1 (en) 2014-03-14 2020-09-02 Daniel J. Capon Compounds useful in preparing hybrid immunoglobulin containing non-peptidyl linkage
US10786551B2 (en) 2007-08-06 2020-09-29 Generon (Shanghai) Corporation Ltd. Use of interleukin-22 in the treatment of fatty liver disease
WO2020264300A1 (en) 2019-06-28 2020-12-30 Genentech, Inc. Composition and methods for stabilizing liquid protein formulations
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244802A (en) 1987-11-18 1993-09-14 Phytogen Regeneration of cotton
US6753463B1 (en) 1987-11-18 2004-06-22 Mycogen Corporation Transformed cotton plants
ATE105585T1 (en) * 1987-12-21 1994-05-15 Univ Toledo TRANSFORMATION OF GERMINATED PLANT SEEDS USING AGROBACTERIUM.
PT89915B (en) * 1988-03-08 1994-10-31 Ciba Geigy Ag PROCESS FOR THE PREPARATION OF CHEMICALLY ADJUSTABLE DNA SEQUENCES
HU219140B (en) * 1992-11-30 2001-02-28 Zeneca Ltd. Dna fragments coding oxalate decarboxylase, recombinant molecules containing them, and transformed plant cells containing the recombinant molecules
US6407313B1 (en) 1995-08-15 2002-06-18 The Regents Of The University Of California Regulation of plant development and physiology through plasmodesmatal macromolecular transport of proteins and oligonucleotides
DE19605279A1 (en) * 1996-02-13 1997-08-14 Hoechst Ag Target cell-specific vectors for the introduction of genes into cells, drugs containing such vectors and their use
US6093695A (en) 1996-09-26 2000-07-25 Monsanto Company Bacillus thuringiensis CryET29 compositions toxic to coleopteran insects and ctenocephalides SPP
US5894079A (en) * 1996-11-15 1999-04-13 Proctor; Larry M. Field bean cultivar named enola
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
EP1717322B1 (en) 1997-01-17 2012-07-18 Codexis Mayflower Holdings, LLC Evolution of whole cells and organisms by recursive sequence recombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
IL137410A0 (en) 1998-02-19 2001-07-24 Cotton Inc A method for the production of transgenic plants using apical shoot tips
US6586658B1 (en) 1998-03-06 2003-07-01 Metabolix, Inc. Modification of fatty acid metabolism in plants
WO2000006747A2 (en) * 1998-07-30 2000-02-10 Metabolix, Inc. Enzymes for biopolymer production
CA2359868A1 (en) 1999-01-14 2000-07-20 Monsanto Company Soybean transformation method
WO2001023595A2 (en) * 1999-09-30 2001-04-05 The University Of Toledo Reduced gravity transformation process and product
BR0016367B1 (en) 1999-12-15 2013-09-03 Method to transform soybean explants tissue
US20030157592A1 (en) * 1999-12-16 2003-08-21 Jens Lerchl Moss genes from physcomitrella patens encoding proteins involved in the synthesis of tocopherols and carotenoids
DK1254238T3 (en) 2000-02-09 2009-11-30 Basf Se New elongase gene and process for producing polyunsaturated fatty acids
ATE454456T1 (en) * 2000-02-11 2010-01-15 Metabolix Inc INTEIN CONTAINING MULTIGEN EXPRESSION CONSTRUCTS
US7176026B2 (en) 2001-11-09 2007-02-13 Basf Plant Science Gmbh Protein kinase stress-related polypeptides and methods of use in plants
US6720477B2 (en) 2000-04-07 2004-04-13 Basf Plant Science Gmbh Signal transduction stress-related proteins and methods of use in plants
US20020129455A1 (en) * 2000-12-19 2002-09-19 Yung-Feng Wei Structure for CD/VCD cleaner
CA2441265A1 (en) 2001-03-16 2002-09-26 Basf Plant Science Gmbh Sugar and lipid metabolism regulators in plants
GB0107510D0 (en) * 2001-03-26 2001-05-16 Univ Bristol New elongase gene and a process for the production of -9-polyunsaturated fatty acids
EP1392104B1 (en) 2001-06-04 2012-08-15 BASF Plant Science GmbH Sugar and lipid metabolism regulators in plants ii
EP1455568A2 (en) * 2001-06-15 2004-09-15 The University Of Toledo Method for transformation of mono- and di- cotyledonous plants using meristematic tissue and nodal callus from dycotiledonous plants
BRPI0211809B1 (en) 2001-08-09 2019-04-24 University Of Saskatchewan METHOD FOR THE CONTROL OF WEED HERBS IN THE NEIGHBORHOODS OF A WHEAT OR TRITICALE PLANT, METHOD FOR MODIFYING THE TOLERANCE OF A WHEAT OR TRITICALE PLANT AND AN IMMEDAZOLINET PRODUCT RESULTING PLANT A HERBICIDE OF IMIDAZOLINONE
ATE426330T1 (en) 2001-08-10 2009-04-15 Basf Plant Science Gmbh SUGAR AND LIPID METABOLISM REGULATORS IN PLANTS III
US20050044595A1 (en) * 2001-08-24 2005-02-24 Diana Arias In planta transformation by embryo imbibition of agrobacterium
CA2459961A1 (en) 2001-09-05 2003-03-13 Basf Plant Science Gmbh Protein phosphatase stress-related polypeptides and methods of use in plants
US20030046733A1 (en) * 2001-09-06 2003-03-06 Dias Kalyani Mallika Transformation of soybeans
US7220585B2 (en) 2001-11-09 2007-05-22 Basf Plant Science Gmbh Transcription factor stress-related polypeptides and methods of use in plants
AU2003209289A1 (en) 2002-05-01 2003-11-17 The University Of Georgia Research Foundation, Inc. Transposable elements in rice and methods of use
US7579517B2 (en) 2002-05-08 2009-08-25 Basf Plant Science Gmbh Methods for increasing oil content in plants
CA2490154A1 (en) * 2002-06-22 2003-12-31 Syngenta Participations Ag Method of transforming soybean
CA2492167C (en) 2002-07-10 2015-06-16 The Department Of Agriculture, Western Australia Wheat plants having increased resistance to imidazolinone herbicides
EP2272966A3 (en) 2002-08-02 2011-07-06 BASF Plant Science GmbH Sugar and lipid metabolism regulators in plants IV
CA2494626A1 (en) 2002-08-07 2004-03-04 Basf Plant Science Gmbh Nucleic acid sequences encoding proteins associated with abiotic stress response
EP2322633A3 (en) 2003-02-17 2011-08-17 Metanomics GmbH Preparation of organisms with faster growth and/or higher yield
US7537920B2 (en) 2003-02-27 2009-05-26 Basf Plant Science Gmbh Method for the production of polyunsaturated fatty acids
CA2520795C (en) 2003-03-31 2015-06-23 University Of Bristol Novel plant acyltransferases specific for long-chained, multiply unsaturated fatty acids
EP1641930B1 (en) 2003-04-15 2011-06-29 BASF Plant Science GmbH Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress
US9382526B2 (en) 2003-05-28 2016-07-05 Basf Aktiengesellschaft Wheat plants having increased tolerance to imidazolinone herbicides
ES2379553T3 (en) 2003-08-29 2012-04-27 Instituto Nacional De Tecnologia Agropecuaria Rice plants that have increased tolerance to imidazolinone herbicides
AU2004309171B2 (en) 2003-12-23 2010-03-04 Basf Plant Science Gmbh Sugar and lipid metabolism regulators in plants VI
KR101179538B1 (en) * 2004-01-20 2012-09-05 (주)인비트로플랜트 A transformation method for viviparous plant
US20050220901A1 (en) * 2004-03-22 2005-10-06 Huttenbauer Samuel Jr Methods of pharmaceutical separation from plants
MXPA06013357A (en) * 2004-06-07 2007-03-01 Basf Plant Science Gmbh Improved transformation of soybean.
CN104178511A (en) 2004-07-31 2014-12-03 梅坦诺米克斯有限公司 Preparation of organisms with faster growth and/or higher yield
WO2006013072A2 (en) 2004-08-02 2006-02-09 Basf Plant Science Gmbh Method for isolation of transcription termination sequences
CA2580736A1 (en) 2004-09-20 2006-03-30 Basf Plant Science Gmbh Arabidopsis genes encoding proteins involved in sugar and lipid metabolism and methods of use
CN103289961A (en) 2004-09-24 2013-09-11 巴斯福植物科学有限公司 Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress
CA2579927A1 (en) 2004-09-24 2006-03-30 Basf Plant Science Gmbh Plant cells and plants with increased tolerance to environmental stress
EP2166100B1 (en) 2005-03-08 2012-07-18 BASF Plant Science GmbH Expression enhancing intron sequences
US7732680B2 (en) 2005-03-16 2010-06-08 Metabolix, Inc. Chemically inducible expression of biosynthetic pathways
CN101203611B (en) 2005-04-19 2013-08-14 巴斯福植物科学有限公司 Improved methods controlling gene expression
CA2612016A1 (en) 2005-06-17 2006-12-21 Basf Plant Science Gmbh Lecitin-like protein kinase stress-related polypeptides and methods of use in plants
EP2333087A1 (en) 2005-07-18 2011-06-15 BASF Plant Science GmbH Yield increase in plants overexpressing the SHSRP genes
CN101228277B (en) 2005-07-18 2013-11-27 巴斯福植物科学有限公司 Yield increase in plants overexpressing ACCDP genes
EP1915452A2 (en) 2005-08-12 2008-04-30 BASF Plant Science GmbH Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress
WO2007039454A1 (en) 2005-09-20 2007-04-12 Basf Plant Science Gmbh Methods for controlling gene expression using ta-siran
EP1974024A2 (en) 2005-12-09 2008-10-01 BASF Plant Science GmbH Nucleic acid molecules encoding polypeptides involved in regulation of sugar and lipid metabolism and methods of use viii
US20090172834A1 (en) 2006-03-24 2009-07-02 Basf Plant Science Gmbh Proteins Associated With Abiotic Stress Response And Homologs
CN101589148B (en) 2006-10-13 2014-07-02 巴斯福植物科学有限公司 Plants with increased yield
CA2681515A1 (en) 2007-03-23 2008-10-02 Basf Plant Science Gmbh Transgenic plants with increased stress tolerance and yield expressing a lrp-2 protein
EP2492345A3 (en) 2007-05-04 2012-12-12 BASF Plant Science GmbH Seed enhancement by combinations of pyruvate kinases
DE112008001452T5 (en) 2007-05-22 2010-12-16 Basf Plant Science Gmbh Plants with increased tolerance and / or resistance to environmental stress and increased biomass production
AU2008257531A1 (en) 2007-05-29 2008-12-04 Basf Plant Science Gmbh Transgenic plants with increased stress tolerance and yield
EP2505653A3 (en) 2007-07-13 2013-05-01 BASF Plant Science GmbH Transgenic plants with increased stress tolerance and yield
CA2694142A1 (en) 2007-08-02 2009-02-05 Basf Plant Science Gmbh Transgenic plants with increased stress tolerance and yield
MX2010002931A (en) 2007-09-18 2010-06-01 Basf Plant Science Gmbh Plants with increased yield.
DE112008002456T5 (en) 2007-09-21 2011-01-13 Basf Plant Science Gmbh Plants with increased yield
WO2009068588A2 (en) 2007-11-27 2009-06-04 Basf Plant Science Gmbh Transgenic plants with increased stress tolerance and yield
CA2709640A1 (en) 2007-12-17 2009-06-25 Basf Plant Science Gmbh Lipid metabolism proteins, combinations of lipid metabolism proteins and uses thereof
US20110041215A1 (en) * 2007-12-17 2011-02-17 Basf Plant Science Gmbh Lipid Metabolism Protein And Uses Thereof I (BZIP Transcription Factor)
BRPI0821748A2 (en) * 2007-12-19 2019-09-24 Basf Plant Science Gmbh method for producing a plant with increased yield, isolated nucleic acid molecule, nucleic acid construction, vector, process for producing a polypeptide, polypeptide, antibody, plant cell nucleus, plant cell, plant tissue, propagation material, seed, pollen, progeny, or a plant part, or a high yielding plant, process for the identification of a compound, method for producing an agricultural composition, composition, polypeptide or nucleic acid molecule, use of nucleic acids, and method for the identification of a plant with increased yield
MX2010009010A (en) * 2008-02-27 2010-09-09 Basf Plant Science Gmbh Plants with increased yield.
CN103923892A (en) 2008-08-19 2014-07-16 巴斯夫植物科学有限公司 Plants with increased yield by increasing or generating one or more activities in a plant or a part thereof
CN102186979A (en) 2008-08-20 2011-09-14 巴斯夫植物科学有限公司 Transgenic plants comprising as transgene a phosphatidate cytidylyltransferase
US20110195843A1 (en) 2008-09-23 2011-08-11 Basf Plant Science Gmbh Plants with Increased Yield (LT)
WO2010034652A1 (en) 2008-09-23 2010-04-01 Basf Plant Science Gmbh Transgenic plants with increased yield
EP2350289A1 (en) 2008-10-23 2011-08-03 BASF Plant Science GmbH Plants with increased yield (nue)
AU2009306369A1 (en) 2008-10-23 2010-04-29 Basf Plant Science Gmbh A method for producing a transgenic cell with increased gamma-aminobutyric acid (GABA) content
MX2011007920A (en) 2009-01-28 2011-09-06 Basf Plant Science Co Gmbh Transgenic plants having altered nitrogen metabolism.
CN102300992A (en) 2009-01-28 2011-12-28 巴斯夫植物科学有限公司 Engineering NF-YB transcription factors for enhanced drought resistance and increased yield in transgenic plants
AU2010221135A1 (en) 2009-03-05 2011-09-29 Metabolix, Inc. Propagation of transgenic plants
WO2010102293A1 (en) 2009-03-06 2010-09-10 Metabolix, Inc. Method of positive plant selection using sorbitol dehydrogenase
CA2754916A1 (en) 2009-03-23 2010-09-30 Basf Plant Science Company Gmbh Transgenic plants with altered redox mechanisms and increased yield
AU2010275363A1 (en) 2009-07-23 2012-02-02 Basf Plant Science Company Gmbh Plants with increased yield
EP2501816A4 (en) 2009-11-17 2013-07-03 Basf Plant Science Co Gmbh Plants with increased yield
CN102971428A (en) 2010-05-04 2013-03-13 巴斯夫欧洲公司 Plants having increased tolerance to herbicides
US8232454B2 (en) * 2010-05-20 2012-07-31 Shyi-Dong Yeh Gene-transfer vector comprising helper-component protease gene of papaya ringspot virus for broad-spectrum virus resistance in crops and use thereof
UA121371C2 (en) 2010-12-16 2020-05-25 Басф Агро Б. В. Plants having increased tolerance to herbicides
CA2867139A1 (en) 2011-04-11 2012-10-18 Targeted Growth, Inc. Identification and the use of krp mutants in plants
WO2013006861A1 (en) 2011-07-07 2013-01-10 University Of Georgia Research Foundation, Inc. Sorghum grain shattering gene and uses thereof in altering seed dispersal
WO2013024121A2 (en) 2011-08-18 2013-02-21 Basf Plant Science Company Gmbh Increase of sucrose transporter activity in the seeds of plants
WO2013184768A1 (en) 2012-06-05 2013-12-12 University Of Georgia Research Foundation, Inc. Compositions and methods of gene silencing in plants
AR091489A1 (en) 2012-06-19 2015-02-11 Basf Se PLANTS THAT HAVE A GREATER TOLERANCE TO HERBICIDES INHIBITORS OF PROTOPORFIRINOGENO OXIDASA (PPO)
US10041087B2 (en) 2012-06-19 2018-08-07 BASF Agro B.V. Plants having increased tolerance to herbicides
CA2881787A1 (en) 2012-08-13 2014-02-20 University Of Georgia Research Foundation, Inc. Compositions and methods for increasing pest resistance in plants
BR112015012645A2 (en) 2012-12-18 2018-10-23 Basf Se methods for nucleic acid production, molecule and construct, vector, polypeptide, plant cell nucleus, transgenic plant, process, composition, use of nucleic acid and method for controlling weeds
BR112016002851B1 (en) 2013-08-12 2022-02-22 BASF Agro B.V. Nucleic acid molecule, nucleic acid construct, vector, ppo polypeptide, method for controlling unwanted vegetation and use of nucleic acid
UA123757C2 (en) 2013-08-12 2021-06-02 Басф Агро Б. В. Plants having increased tolerance to herbicides
EP3062606B1 (en) 2013-10-29 2019-03-20 Biotech Institute, LLC Breeding, production, processing and use of specialty cannabis
WO2015150465A2 (en) 2014-04-03 2015-10-08 Basf Se Plants having increased tolerance to herbicides
MX2017009541A (en) 2015-01-21 2018-05-07 Basf Se Plants having increased tolerance to herbicides.
BR112017016789A2 (en) 2015-02-11 2018-05-08 Basf Se methods for producing a transgenic plant, for controlling unwanted vegetation and for plant cultivation, nucleic acid molecule, nucleic acid construction, vector, mutated hppd polypeptide, plant cell nucleus, transgenic plant cell nucleus, transgenic plant, use of nucleic acid, useful combination, process for preparing a useful combination and use of a useful combination
MA45030A (en) 2016-05-20 2019-03-27 Basf Agro Bv DOUBLE TRANSIT PEPTIDES FOR TARGETING POLYPEPTIDES
AU2017294685B2 (en) 2016-07-15 2023-10-26 Basf Se Plants having increased tolerance to herbicides
CN109790153A (en) 2016-07-27 2019-05-21 巴斯夫农业公司 Plant with increased herbicide tolerant
EP3559243A1 (en) 2016-12-20 2019-10-30 BASF Agro B.V. Plants having increased tolerance to herbicides
WO2019106568A1 (en) 2017-11-29 2019-06-06 Basf Se Plants having increased tolerance to herbicides
EA202091721A1 (en) 2018-01-17 2020-11-27 Басф Се PLANTS WITH INCREASED HERBICIDE RESISTANCE
CN108642079A (en) * 2018-06-11 2018-10-12 吉林省农业科学院 A kind of corn genetic transformation method of non-tissue cultures
CN115605082A (en) * 2019-11-26 2023-01-13 先正达农作物保护股份公司(Ch) Transformation method
WO2022093977A1 (en) 2020-10-30 2022-05-05 Fortiphyte, Inc. Pathogen resistance in plants
AU2022340861A1 (en) 2021-09-03 2024-03-14 BASF Agricultural Solutions Seed US LLC Plants having increased tolerance to herbicides
WO2024052856A1 (en) 2022-09-09 2024-03-14 Friedrich Alexander Universität Erlangen-Nürnberg Plant regulatory elements and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0064720A2 (en) * 1981-05-04 1982-11-17 The Research And Development Institute Inc. At Montana State University Compositions containing and methods of use of an infectivity-cured Hr plasmid-bearing microorganism
FR2560744A1 (en) * 1983-10-26 1985-09-13 Phytogen Prod Inc Method for the genetic transformation of dicotyledonous plant seeds in order to favour the growth of seminal roots, and seeds thus obtained.
EP0241963A1 (en) * 1986-03-26 1987-10-21 "Centre d'Etude de l'Energie Nucléaire", "C.E.N." Process for treating plant material to obtain the expression of at least one gene, and plant material in which that gene is expressed
EP0256751A2 (en) * 1986-08-04 1988-02-24 Lubrizol Genetics Inc. Transformation, somatic embryogenesis and whole plant regeneration method for glycine species
EP0267159A2 (en) * 1986-11-07 1988-05-11 Ciba-Geigy Ag Process for the genetic modification of monocotyledonous plants
EP0301749A2 (en) * 1987-07-29 1989-02-01 Agracetus, Inc. Particle-mediated transformation of soybean plants and lines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE105585T1 (en) * 1987-12-21 1994-05-15 Univ Toledo TRANSFORMATION OF GERMINATED PLANT SEEDS USING AGROBACTERIUM.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0064720A2 (en) * 1981-05-04 1982-11-17 The Research And Development Institute Inc. At Montana State University Compositions containing and methods of use of an infectivity-cured Hr plasmid-bearing microorganism
FR2560744A1 (en) * 1983-10-26 1985-09-13 Phytogen Prod Inc Method for the genetic transformation of dicotyledonous plant seeds in order to favour the growth of seminal roots, and seeds thus obtained.
EP0241963A1 (en) * 1986-03-26 1987-10-21 "Centre d'Etude de l'Energie Nucléaire", "C.E.N." Process for treating plant material to obtain the expression of at least one gene, and plant material in which that gene is expressed
EP0256751A2 (en) * 1986-08-04 1988-02-24 Lubrizol Genetics Inc. Transformation, somatic embryogenesis and whole plant regeneration method for glycine species
EP0267159A2 (en) * 1986-11-07 1988-05-11 Ciba-Geigy Ag Process for the genetic modification of monocotyledonous plants
EP0301749A2 (en) * 1987-07-29 1989-02-01 Agracetus, Inc. Particle-mediated transformation of soybean plants and lines

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Biological Abstracts/RRM W. Lin et al.: "Soybean tissue culture and genetic transformation" *
Biological Abstracts/RRM, no. 89:116856 T.C. Hall et al.: "Transformation of plant cells" *
Chemical Abstracts. vol. 109, 1988, (Columbus, Ohio, US) see page 193 *
J. Cell Biochem. Suppl. 11B, S.L. Goldman et al.: "Transformation of Zea mays by Agrobacterium tumefaciens: Evidence for stable genetic alterrations", page 26 *
Mol.Gen Genet, vol. 208, no. 1/2, June 1987, Spring-Verlag K.A. Feldmann et al.: "Agrobacteriummediated transformation of germinating seeds of Arabidopsis thaliana: A nontissue culture approach", pages 1-9 *
Nature, vol. 325, no. 7000, 7-14 January 1987, (Neptune, NJ, US) N. Grimsley et al.: "Agrobacteriummediated delivery of infectious maize streak virus into maize plants", pages 177-179 *
Plant Mol. Biol., vol. 8, no. 3, 1987, M. Nijhoff Publishers, Dordrecht (NL) K. Sukhapinda et al.: "Ri-plasmid as a helper for introducing vector DNA into alfalfa plants", pages 209-216 *
Plant. Molecular Biology, vol. 7, 1986 M. Nijfhoff Publishers, Dordrecht (NL) A.C.F. Graves et al.: "The transformation of Zea mays seedlings with Agrobacterium tumefaciens" pages 43-50 *

Cited By (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004332A1 (en) * 1989-09-20 1991-04-04 The Upjohn Company Somatic embryogenesis of squash
EP0424047A1 (en) * 1989-10-17 1991-04-24 Pioneer Hi-Bred International, Inc. Tissue culture method for transformation of plant cells
US7033627B2 (en) 1990-03-23 2006-04-25 Syngenta Mogen B.V. Production of enzymes in seeds and their use
US5543576A (en) * 1990-03-23 1996-08-06 Mogen International Production of enzymes in seeds and their use
US5714474A (en) * 1990-03-23 1998-02-03 Mogen International Production of enzymes in seeds and their use
US5593963A (en) * 1990-09-21 1997-01-14 Mogen International Expression of phytase in plants
WO1992006205A1 (en) * 1990-09-27 1992-04-16 Clovis Matton N.V. A process for the gene manipulation of plant cells, recombinant plasmids, recombinant bacteria, plants
US6160201A (en) * 1993-07-09 2000-12-12 Seminis Vegetable Seeds, Inc. Lettuce infectious yellows virus genes
EP1382679A2 (en) 1995-09-08 2004-01-21 Genentech, Inc. Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6746668B2 (en) 1996-01-09 2004-06-08 Genentech, Inc. Apo-2 ligand
US7285533B2 (en) 1996-01-09 2007-10-23 Genentech, Inc. Apo-2 ligand
US6469144B1 (en) 1996-04-01 2002-10-22 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US6407216B1 (en) 1996-09-30 2002-06-18 Genentech, Inc. Vertebrate smoothened antibodies
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US7749755B2 (en) 1997-05-15 2010-07-06 Genentech, Inc. Apo-2 receptor polynucleotides
US7314619B2 (en) 1997-05-15 2008-01-01 Genentech, Inc. Inducing apoptosis using anti-Apo-2 antibodies
US8092799B2 (en) 1997-05-15 2012-01-10 Genentech, Inc. Antibodies to Apo-2 receptor polypeptides
US7595046B2 (en) 1997-05-15 2009-09-29 Genentech, Inc. Treatment of cancer using anti-Apo-2 antibodies
US7750118B2 (en) 1997-05-15 2010-07-06 Genentech, Inc. Apo-2 receptor polypeptides
US7939631B2 (en) 1997-05-15 2011-05-10 Genentech, Inc. APO-2 receptor polypeptides
US7807153B2 (en) 1997-05-15 2010-10-05 Genentech, Inc. Apo-2 receptor agonist antibodies
US6291643B1 (en) 1997-06-05 2001-09-18 Board Of Reports, The University Of Texas System Apaf-1 an activator of caspase-3
EP2083079A1 (en) 1997-06-18 2009-07-29 Genentech, Inc. Apo-2DcR
EP1958965A2 (en) 1997-08-25 2008-08-20 Genentech, Inc. Agonist antibodies to a musk receptor, and their therapeutic uses
US6764679B2 (en) 1997-09-18 2004-07-20 Genentech, Inc. Antibodies to DcR3 Polypeptide, a TNFR Homolog
EP1967587A1 (en) 1997-10-10 2008-09-10 Genentech, Inc. APO-3 Ligand
EP2033970A2 (en) 1997-10-29 2009-03-11 Genentech, Inc. WNT-1 inducible genes
EP2014770A2 (en) 1997-10-29 2009-01-14 Genentech, Inc. WNT-1 Iinduced secreted polypeptide WISP-2
EP2014677A1 (en) 1997-11-21 2009-01-14 Genentech, Inc. A-33 related antigens and their pharmacological uses
EP2017341A2 (en) 1998-01-15 2009-01-21 Genentech, Inc. Apo-2 ligand
US6740739B1 (en) 1998-01-15 2004-05-25 Genentech, Inc. Substitutional variants of APO-2 ligand
US7342099B2 (en) 1998-02-25 2008-03-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services cDNA encoding a gene BOG (B5T over-expressed gene) and its protein product
US6727079B1 (en) 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
EP2050762A2 (en) 1998-03-10 2009-04-22 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
EP1865061A2 (en) 1998-05-15 2007-12-12 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP2333069A2 (en) 1998-05-15 2011-06-15 Genentech, Inc. Therapeutic uses of IL-17 homologous polypeptides
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP2075335A2 (en) 1998-12-22 2009-07-01 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP1820859A2 (en) 1998-12-22 2007-08-22 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP2330198A1 (en) 1998-12-23 2011-06-08 Genentech, Inc. IL-1 related polypeptides
EP2319929A1 (en) 1998-12-23 2011-05-11 Genentech, Inc. IL-1 related polypeptides
WO2000037663A3 (en) * 1998-12-23 2000-11-09 Samuel Roberts Noble Found Inc Plant transformation process
WO2000037663A2 (en) * 1998-12-23 2000-06-29 The Samuel Roberts Noble Foundation, Inc. Plant transformation process
EP1953173A1 (en) 1999-06-15 2008-08-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
EP1956030A1 (en) 1999-06-15 2008-08-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
EP2311956A1 (en) 1999-06-28 2011-04-20 Genentech, Inc. Methods for making APO-2 ligand using divalent metal ions
EP2339003A2 (en) 1999-06-28 2011-06-29 Genentech, Inc. APO-2 ligand substitutional variants
EP2228446A1 (en) 1999-12-01 2010-09-15 Genentech, Inc. Secreted and transmembrane polypeptieds and nucleic acids encoding the same
EP2258848A1 (en) 1999-12-23 2010-12-08 Genentech, Inc. Il-17 homologous polypeptide and therapeutic uses thereof
EP2290081A2 (en) 1999-12-23 2011-03-02 Genentech, Inc. IL-17 homologous polypeptide and therapeutic uses thereof
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1757701A1 (en) 1999-12-24 2007-02-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1757311A2 (en) 1999-12-24 2007-02-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US6555335B1 (en) 1999-12-30 2003-04-29 Genencor International, Inc. Xylanase from Trichoderma reesei , method for production thereof, and methods employing this enzyme
US6768001B2 (en) 1999-12-30 2004-07-27 Genencor International, Inc. Xylanase from trichoderma reesei, method for production thereof, and methods employing this enzyme
US7741439B2 (en) 2000-01-13 2010-06-22 Genentech, Inc. Isolated stra6 polypeptides
US7939650B2 (en) 2000-01-13 2011-05-10 Genentech, Inc. Stra6 polypeptides
US7173115B2 (en) 2000-01-13 2007-02-06 Genentech, Inc. Stra6 polypeptides
US7855278B2 (en) 2000-01-13 2010-12-21 Genentech, Inc. Antibodies to Stra6 polypeptides
EP1666052A1 (en) 2000-02-16 2006-06-07 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
EP2042597A1 (en) 2000-06-23 2009-04-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2792747A1 (en) 2000-06-23 2014-10-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2075253A1 (en) 2000-06-23 2009-07-01 Genentech, Inc. Compositions and methds for the diagnosis and treatment of disorders involving angiogensis
EP2075334A1 (en) 2000-06-23 2009-07-01 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and methods of use
EP2077276A1 (en) 2000-06-23 2009-07-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
EP2275549A1 (en) 2000-06-23 2011-01-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2168980A1 (en) 2000-06-23 2010-03-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
EP2014298A2 (en) 2000-08-24 2009-01-14 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP1944317A2 (en) 2000-09-01 2008-07-16 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2116265A2 (en) 2000-10-12 2009-11-11 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2002030463A2 (en) 2000-10-12 2002-04-18 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
EP2305823A1 (en) 2001-01-15 2011-04-06 Wista Laboratories Ltd. Materials and methods relating to protein aggregation in neurodegenerative disease
EP2065467A2 (en) 2001-02-22 2009-06-03 Genentech, Inc. Anti-interferon-alpha antibodies
EP2292301A2 (en) 2001-02-22 2011-03-09 Genentech, Inc. Anti-interferon-alpha antibodies
EP1236801A3 (en) * 2001-02-26 2002-10-02 The Agri-Biotechnology Research Center of Shanxi Method of agrobacterium mediated plant transformation through treatment of germinating seeds
EP1236801A2 (en) * 2001-02-26 2002-09-04 The Agri-Biotechnology Research Center of Shanxi Method of agrobacterium mediated plant transformation through treatment of germinating seeds
EP2000545A1 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2000148A1 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of prostate cancer
EP1992643A2 (en) 2001-06-20 2008-11-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2000482A1 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2311960A2 (en) 2001-08-29 2011-04-20 Genentech, Inc. Bv8 nucleic acids and polypeptides with mitogenic activity
EP2151244A1 (en) 2001-09-18 2010-02-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2143438A1 (en) 2001-09-18 2010-01-13 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2153843A1 (en) 2001-09-18 2010-02-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2348043A1 (en) 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
EP2332531A1 (en) 2001-11-13 2011-06-15 Genentech, Inc. Apo2 ligand/TRAIL formulations
EP2322165A1 (en) 2001-11-13 2011-05-18 Genentech, Inc. Apo2 ligand/TRAIL formulations
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
EP2388265A1 (en) 2002-02-22 2011-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2011886A2 (en) 2002-04-16 2009-01-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7705195B2 (en) 2002-06-07 2010-04-27 Genentech, Inc. Screening method
EP2500032A1 (en) 2002-06-24 2012-09-19 Genentech, Inc. APO-2 ligand/trail variants and uses thereof
EP2332956A1 (en) 2002-07-08 2011-06-15 Genentech, Inc. Antibody binding to PRO71238
EP2085096A2 (en) 2002-09-11 2009-08-05 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
EP2116551A1 (en) 2002-09-11 2009-11-11 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2444409A2 (en) 2002-09-16 2012-04-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2500438A2 (en) 2002-09-25 2012-09-19 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
EP2434022A2 (en) 2002-10-03 2012-03-28 Genentech, Inc. Use of A33 antigens and JAM-IT
EP1895017A2 (en) 2002-10-03 2008-03-05 Genentech, Inc. Use of A33 antigens and JAM-IT
EP2322202A2 (en) 2002-10-29 2011-05-18 Genentech, Inc. Compositions and methods for the treatment of immune diseases
EP2322201A2 (en) 2002-10-29 2011-05-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2322200A2 (en) 2002-10-29 2011-05-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2322203A2 (en) 2002-10-29 2011-05-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2364716A2 (en) 2002-11-08 2011-09-14 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
EP2311870A1 (en) 2002-11-26 2011-04-20 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2311868A1 (en) 2002-11-26 2011-04-20 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2308968A1 (en) 2002-11-26 2011-04-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2314676A1 (en) 2002-11-26 2011-04-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2526960A1 (en) 2003-03-12 2012-11-28 Genentech, Inc. Use of BV8 and/or EG-VEGF to promote hematopoiesis
EP3178492A1 (en) 2003-04-04 2017-06-14 Genentech, Inc. High concentration antibody and protein formulations
EP2335725A1 (en) 2003-04-04 2011-06-22 Genentech, Inc. High concentration antibody and protein formulations
EP2083018A2 (en) 2003-04-16 2009-07-29 Genentech, Inc. Compositions and methods relating to STOP-1
EP2272868A2 (en) 2003-06-05 2011-01-12 Genentech, Inc. Combination therapy for B cell disorders
EP2277908A2 (en) 2003-07-08 2011-01-26 Genentech, Inc. IL-17A/F heterologous polypeptides, antibodies and therapeutic uses thereof
EP2784084A1 (en) 2003-07-08 2014-10-01 Genentech, Inc. IL-17 A/F heterologous polypeptides and therapeutics uses thereof
EP3594228A1 (en) 2003-07-08 2020-01-15 Genentech, Inc. Il-17a/f heterologous polypedtides and therapeutic uses thereof
EP2014675A1 (en) 2003-08-11 2009-01-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2256134A1 (en) 2003-11-13 2010-12-01 Hanmi Pharmaceutical Co., Ltd. IgG Fc fragment for a drug carrier and method for the preparation thereof
EP2161283A1 (en) 2003-11-17 2010-03-10 Genentech, Inc. Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin
EP2295073A1 (en) 2003-11-17 2011-03-16 Genentech, Inc. Antibody against CD22 for the treatment of tumour of hematopoietic origin
EP2301568A1 (en) 2003-11-17 2011-03-30 Genentech, Inc. Antibody against IRTA2 for the treatment of tumour of hematopoietic origin
US8217223B2 (en) 2004-06-16 2012-07-10 Basf Plant Science Gmbh Nucleic acid molecules encoding WRINKLED1-like polypeptides and methods of use in plants
EP2186402A1 (en) 2005-06-06 2010-05-19 Genentech, Inc. Knock-out animal models for novel genes and methods of use
EP1995321A2 (en) 2005-08-15 2008-11-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2002714A1 (en) 2005-11-21 2008-12-17 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2050335A1 (en) 2006-02-17 2009-04-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2389946A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2389951A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2389948A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2389949A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2389947A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2389950A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2614839A2 (en) 2006-04-05 2013-07-17 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP3026123A1 (en) 2006-04-27 2016-06-01 Klaritos, Inc. Method and kit for predicting antibody therapy
WO2008033890A2 (en) 2006-09-12 2008-03-20 Beth Israel Deaconess Medical Center, Inc. Compositions containing alpha-1-antitrypsin and methods for use
EP3284825A1 (en) 2006-11-02 2018-02-21 Daniel J. Capon Methods of producing hybrid polypeptides with moving parts
EP2450050A1 (en) 2006-11-29 2012-05-09 Genentech, Inc. IL-17A/F heterodimeric polypeptides and therapeutic uses thereof
EP3181147A1 (en) 2006-11-29 2017-06-21 Genentech, Inc. Il-17a/f heterodimeric polypeptides and therapeutic thereof
EP2436781A1 (en) 2007-02-22 2012-04-04 Genentech, Inc. Methods for detecting inflammatory bowel disease
EP2474557A2 (en) 2007-07-16 2012-07-11 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
EP2641618A2 (en) 2007-07-16 2013-09-25 Genentech, Inc. Humanized anti-CD79B antibodies and immunoconjugates and methods of use
EP2502937A2 (en) 2007-07-16 2012-09-26 Genentech, Inc. Anti-CD 79b Antibodies And Immunoconjugates And Methods Of Use
US10786551B2 (en) 2007-08-06 2020-09-29 Generon (Shanghai) Corporation Ltd. Use of interleukin-22 in the treatment of fatty liver disease
EP2233149A1 (en) 2007-10-16 2010-09-29 ZymoGenetics, Inc. Combination of BLYS inhibition and anti-CD20 agents for treatment of autoimmune disease
EP2657253A2 (en) 2008-01-31 2013-10-30 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
EP3208612A1 (en) 2008-04-09 2017-08-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP3605088A1 (en) 2008-04-09 2020-02-05 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP3002295A1 (en) 2008-04-28 2016-04-06 Genentech, Inc. Humanized anti-factor d antibodies and uses thereof
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
EP3309168A1 (en) 2009-08-06 2018-04-18 F. Hoffmann-La Roche AG Method to improve virus removal in protein purification
US10662237B2 (en) 2009-08-06 2020-05-26 Genentech, Inc. Method to improve virus filtration capacity
WO2011031397A1 (en) 2009-08-06 2011-03-17 Genentech, Inc. Method to improve virus removal in protein purification
US11225513B2 (en) 2009-08-06 2022-01-18 Genentech, Inc. Method to improve virus filtration capacity
US8512983B2 (en) 2009-08-11 2013-08-20 Martin Gawlitzek Production of proteins in glutamine-free cell culture media
US10982003B2 (en) 2009-08-11 2021-04-20 Genentech, Inc. Production of proteins in glutamine-free cell culture media
US9714293B2 (en) 2009-08-11 2017-07-25 Genentech, Inc. Production of proteins in glutamine-free cell culture media
EP3760712A1 (en) 2009-08-11 2021-01-06 F. Hoffmann-La Roche AG Production of proteins in glutamine-free cell culture media
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
US8535912B2 (en) 2009-10-15 2013-09-17 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011060246A2 (en) 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
WO2011066503A2 (en) 2009-11-30 2011-06-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP3002297A2 (en) 2009-11-30 2016-04-06 F. Hoffmann-La Roche AG Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211)
WO2011106297A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011139985A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011150110A1 (en) 2010-05-25 2011-12-01 Genentech, Inc. Methods of purifying polypeptides
EP3299380A1 (en) 2010-05-25 2018-03-28 F. Hoffmann-La Roche AG Methods of purifying polypeptides
EP3332798A1 (en) 2010-08-31 2018-06-13 Generon (Shanghai) Corporation Ltd. Use of interleukin-22 in treating viral hepatitis
WO2012036884A2 (en) 2010-09-15 2012-03-22 Aligna Technologies, Inc. Bioproduction of aromatic chemicals from lignin-derived compounds
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
WO2013163606A1 (en) 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vascular endothelial growth factor antagonists and methods for their use
US9278131B2 (en) 2012-08-10 2016-03-08 Adocia Process for lowering the viscosity of highly concentrated protein solutions
WO2014088940A1 (en) 2012-12-07 2014-06-12 Danisco Us Inc. Compositions and methods of use
WO2014088934A1 (en) 2012-12-07 2014-06-12 Danisco Us Inc. Compositions and methods of use
US9879245B2 (en) 2012-12-07 2018-01-30 Danisco Us Inc. Polypeptides having beta-mannanase activity and methods of use
US10544198B2 (en) 2013-03-15 2020-01-28 Genentech, Inc. Methods of accelerating or improving wound healing using IL-22 FC fusion proteins
US11136365B2 (en) 2013-03-15 2021-10-05 Genentech, Inc. Methods for preventing or treating cardiovascular conditions using il-22 fc fusion proteins
US11332507B2 (en) 2013-03-15 2022-05-17 Genentech, Inc. IL-22 Fc fusion proteins
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
US11155591B2 (en) 2013-03-15 2021-10-26 Genentech, Inc. Methods of treating acute pancreatitis using IL-22 fc fusion proteins
US10087227B2 (en) 2013-03-15 2018-10-02 Genentech, Inc. Nucleic acids encoding IL-22 Fc fusion proteins
EP3385277A1 (en) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Il-22 polypeptides and il-22 fc fusion proteins and methods of use
EP4039281A1 (en) 2013-03-15 2022-08-10 Biomolecular Holdings LLC Hybrid immunoglobulin containing non-peptidyl linkage
US10160793B2 (en) 2013-03-15 2018-12-25 Genentech, Inc. Methods of treating inflammatory bowel disease using IL-22 Fc fusion proteins
US10584155B2 (en) 2013-03-15 2020-03-10 Genentech, Inc. Pharmaceutical compositions of IL-22 Fc fusion proteins
US9815880B2 (en) 2013-03-15 2017-11-14 Genentech, Inc. IL-22 Fc fusion proteins
US11130791B2 (en) 2013-03-15 2021-09-28 Genentech, Inc. Methods for treating metabolic syndrome using IL-22 Fc fusion proteins
EP3611180A1 (en) 2013-03-15 2020-02-19 Daniel J. Capon Hybrid immunoglobulin containing non-peptidyl linkage
WO2014144911A2 (en) 2013-03-15 2014-09-18 Capon Daniel J Hybrid immunoglobulin containing non-peptidyl linkage
US10543169B2 (en) 2013-11-07 2020-01-28 Generon (Shanghai) Corporation Ltd. Use of IL-22 dimer in manufacture of a medicament for intravenous administration
US11654104B2 (en) 2013-11-07 2023-05-23 Evive Biotechnology (Shanghai) Ltd Use of IL-22 dimer in manufacture of a medicament for intravenous administration
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
EP4169944A1 (en) 2014-03-14 2023-04-26 Biomolecular Holdings LLC Process for preparing hybrid immunoglobulin containing non-peptidyl linkage
EP3701971A1 (en) 2014-03-14 2020-09-02 Daniel J. Capon Compounds useful in preparing hybrid immunoglobulin containing non-peptidyl linkage
WO2016054185A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta-mannanase and methods of use
WO2016054168A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta mannanase and methods of use
WO2016054205A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta mannanase and methods of use
WO2016054194A1 (en) 2014-09-30 2016-04-07 1/1Danisco Us Inc Compositions comprising beta-mannanase and methods of use
WO2016054176A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta-mannanase and methods of use
WO2016100825A1 (en) 2014-12-18 2016-06-23 Danisco Us Inc Engineered multifunctional enzymes and methods of use
WO2016100837A1 (en) 2014-12-18 2016-06-23 Danisco Us Inc Engineered multifunctional enzymes and methods of use
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP4230649A2 (en) 2017-04-25 2023-08-23 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
WO2019148020A1 (en) 2018-01-26 2019-08-01 Genentech, Inc. Compositions and methods of use
WO2019148026A1 (en) 2018-01-26 2019-08-01 Genentech, Inc. Il-22 fc fusion proteins and methods of use
WO2019165140A1 (en) 2018-02-21 2019-08-29 Genentech, Inc. DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
WO2020264300A1 (en) 2019-06-28 2020-12-30 Genentech, Inc. Composition and methods for stabilizing liquid protein formulations
US11865177B2 (en) 2019-06-28 2024-01-09 Genentech, Inc. Composition and methods for stabilizing liquid protein formulations
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof

Also Published As

Publication number Publication date
DK126690D0 (en) 1990-05-22
EP0397687A1 (en) 1990-11-22
ATE105585T1 (en) 1994-05-15
AU648951B2 (en) 1994-05-05
US5169770A (en) 1992-12-08
AU2818789A (en) 1989-07-19
US5376543A (en) 1994-12-27
JPH04501201A (en) 1992-03-05
DK126690A (en) 1990-05-22
KR900700605A (en) 1990-08-16
AU3715293A (en) 1993-08-05
KR0154872B1 (en) 1998-10-15
DE3889546T2 (en) 1994-09-08
EP0397687B1 (en) 1994-05-11
AU633248B2 (en) 1993-01-28
DE3889546D1 (en) 1994-06-16

Similar Documents

Publication Publication Date Title
US5376543A (en) Agrobacterium mediated transformation of germinating plant seeds
JP3665321B2 (en) Enhanced expression in plants
Men et al. Agrobacterium-mediated genetic transformation of a Dendrobium orchid
Elliott et al. Cis-acting elements for light regulation of pea ferredoxin I gene expression are located within transcribed sequences.
Rao et al. Agrobacterium-mediated Transformation of Sunflower (Helianthus annuusL.): A Simple Protocol
EP0459643A2 (en) A recombinant promoter for gene expression in monocotyledonous plants
WO1985004899A1 (en) Methods and vectors for transformation of plant cells
US5073675A (en) Method of introducing spectinomycin resistance into plants
KR100477413B1 (en) Improved integration of exogenous DNA delivered to eukaryotic cells
HUT58758A (en) New signalsequencies
EP0573767B1 (en) Process for production of exogenous gene or its product in plant cells
WO2012065528A1 (en) Identification and use of plant root-specific expression promoter
CA2037677C (en) Process for production of exogenous gene or its product in plant cells
JP2002525033A (en) Pi-ta gene that confers disease resistance to plants
JP5186076B2 (en) Engineering plant senescence using the myb gene promoter and cytokinin biosynthesis genes
EP0592685B1 (en) Plant resistant to two or more viruses and preparation thereof
US7557264B2 (en) Gossypium hirsutum tissue-specific promoters and their use
US6664384B1 (en) Duplicated cassava vein mosaic virus enhancers and uses thereof
EP0223417A1 (en) TL-based sub-T-DNA plasmids
US5959181A (en) Method of preparation of transgenic plants resistant to viral infections and so obtained plants
OĞRAŞ et al. Expression and inheritance of GUS gene in transgenic tobacco plants
NZ207766A (en) Plant structural gene expression
AU769546B2 (en) Method for obtaining transgenic plants expressing a protein with activity producing hydrogen peroxide by transformation by Agrobacterium rhizogenes
JP3098353B2 (en) Production of foreign genes and their products in plant cells
Chen et al. A manuscript to be submitted to Plant Science

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI JP KR NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989900780

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989900780

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1989900780

Country of ref document: EP